

CITATION REPORT

List of articles citing

Nivolumab versus Everolimus in Advanced Renal-Cell Carcin

DOI: 10.1056/nejmoa1510665

New England Journal of Medicine, 2015, 373, 1803-13.

Source: <https://exaly.com/paper-pdf/62435055/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2278	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. 2017 , 6, 220-229		9
2277	Tyrosine kinase inhibitors in renal cell cancer: Losing an empire and yet to find a role. 2015 , 51, 2578-9		
2276	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. 2015 , 3, 1292-8		21
2275	Metastatic renal cell carcinoma: Contending with a sea change in therapy. 2015 , 33, 507-8		8
2274	A Delicate Balance--Pharmaceutical Innovation and Access. <i>New England Journal of Medicine</i> , 2015 , 373, 1799-801	59.2	5
2273	Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. <i>New England Journal of Medicine</i> , 2015 , 373, 1872-4	59.2	17
2272	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1814-23	59.2	762
2271	Immunity and HER2-positive disease: never stop questioning. 2015 , 26, 2361-2		2
2270	Combination therapy in kidney cancer: the next revolution?. 2015 , 16, 1441-1442		6
2269	CheckMate for advanced-stage ccRCC? Nivolumab and cabozantinib aMETEORate poor survival. 2015 , 12, 651		
2268	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. 2015 , 41, 868-76		280
2267	The Paradox of Anti-cancer Agents and Recurring Emergence of Drug Resistance. 2016 , 05,		
2266	Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors. 2016 , 10, S242-S244		1
2265	Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib. 2016 , 20, 15-149		2
2264	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. 2016 , 7, 52810-52817		250
2263	Contemporary Treatment of Metastatic Renal Cell Carcinoma. 2016 , 10, 295		29
2262	Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. 2016 , 10, 2167-72		15

2261	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. 2016 , 10, 293	38
2260	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112	43
2259	Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics. 2016 , 9, 7309-7314	2
2258	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. 2016 , 9, 3187-95	11
2257	Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. 2016 , 10, 676	4
2256	Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. 2016 , 11, 23-36	34
2255	T cell Bim levels reflect responses to anti-PD-1 cancer therapy. 2016 , 1,	52
2254	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. 2016 , 7, 771-788	61
2253	The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. 2016 , 35, 113-7	10
2252	The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies. 2016 , 35, e16-20	6
2251	Immunotherapy in urothelial carcinoma: fade or future standard?. 2016 , 5, 662-667	2
2250	Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice. 2016 , 5, 974-976	2
2249	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. 2016 , 24, 7	3
2248	Drugs That Act on the Immune System. 2016 , 395-405	1
2247	Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. 2016 , 7, 77404-77415	115
2246	The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. 2016 , 113, 590-6	15
2245	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. 2016 , 7, 54564-54571	89
2244	PD-1 blockade enhances the vaccination-induced immune response in glioma. 2016 , 1,	103

2243	Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. 2016 , 9, 65-72	3
2242	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. 2016 , 9, 5825-5837	20
2241	Harnessing the immune system to improve cancer therapy. 2016 , 4, 261	167
2240	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. 2016 , 7, 550	282
2239	Systemic Immunotherapy for the Treatment of Brain Metastases. 2016 , 6, 49	56
2238	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. 2016 , 6, 233	94
2237	Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. 2016 , 6, 250	14
2236	Prognostic Value of Plasma and Urine Glycosaminoglycan Scores in Clear Cell Renal Cell Carcinoma. 2016 , 6, 253	16
2235	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
2234	Retrospective Study of Metastatic Melanoma and Renal Cell Carcinoma to the Brain with Multivariate Analysis of Prognostic Pre-Treatment Clinical Factors. 2016 , 17, 400	7
2233	Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma. 2016 , 17, 573	56
2232	Role of mTOR Inhibitors in Kidney Disease. 2016 , 17,	29
2231	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. 2016 , 17,	93
2230	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. 2016 , 17,	41
2229	Immunotherapy for Gastroesophageal Cancer. 2016 , 5,	35
2228	Insulin-like growth factor-1 signaling in renal cell carcinoma. 2016 , 16, 453	30
2227	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. 2016 , 4, 13	131
2226	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. 2016 , 11, e0160485	25

2225	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. 2016 , 10, 3153-3161	19
2224	Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study. 2016 , 7, 331	12
2223	The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. 2016 , 7, 74350-74361	31
2222	Combination therapy for metastatic renal cell carcinoma. 2016 , 4, 100	16
2221	Radiation therapy and the abscopal effect: a concept comes of age. 2016 , 4, 118	51
2220	Kidney cancer drug is available on the Early Access to Medicines Scheme. 2016 , 8, 98-98	
2219	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. 2016 , 7, 73068-73079	60
2218	Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs. 2016 , 7, 15801-10	4
2217	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. 2016 , 22, 96-100	4
2216	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
2215	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+);LSL-Trp53(R172H/+);Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. 2016 , 73, 14.39.1-14.39.20	88
2214	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. 2016 , 22, 68-72	26
2213	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. 2016 , 8, 319-326	20
2212	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors. 2016 , 40, 1133-42	62
2211	Immune Checkpoint Therapy in Renal Cell Carcinoma. 2016 , 22, 92-5	18
2210	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. 2016 , 28, 254-63	157
2209	Immunotherapy advances in uro-genital malignancies. 2016 , 105, 52-64	16
2208	HIV and renal cell carcinoma: Experience in an Australian statewide HIV center. 2016 , 12, 188-93	4

2207	Immune-mediated respiratory adverse events of checkpoint inhibitors. 2016 , 28, 269-77	33
2206	Rare side-effects of checkpoint inhibitors. 2016 , 28, 295-305	6
2205	Chemotherapy-sparing treatment strategies for follicular lymphoma: current options and future directions. 2016 , 23, 371-6	
2204	Immune checkpoint inhibitors side effects and management. 2016 , 8, 799-807	42
2203	Immune Checkpoint Therapies in Prostate Cancer. 2016 , 22, 117-20	34
2202	Recent advances in immuno-oncology and its application to urological cancers. 2016 , 118, 506-14	11
2201	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. 2016 , 115, 252-60	51
2200	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. 2016 , 46, 875-8	61
2199	Immunotherapy for genitourinary cancer: state of the art and new perspectives. 2016 , 27, 585-99	4
2198	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. 2016 , 100, 242-51	66
2197	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of tamsirolimus and future directions. 2016 , 12, 533-49	6
2196	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. 2016 , 1, e000122	40
2195	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. 2016 , 81, 219-226	4
2194	Immunotherapy for breast cancer: past, present, and future. 2016 , 35, 525-546	27
2193	AACR Cancer Progress Report 2016. 2016 , 22 Suppl 19, S1-S137	27
2192	Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. 2016 , 8, 338-347	18
2191	The role of immune checkpoint inhibition in the treatment of ovarian cancer. 2016 , 3, 11	96
2190	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. 2016 , 17, e542-e551	842

2189	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. 2016 , 8, 1383-1391	14
2188	The cost and value of cancer drugs - are new innovations outpacing our ability to pay?. 2016 , 5, 40	12
2187	Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices. 2016 , 103 Suppl 1, S151-S159	4
2186	Cancer immunotherapy trials: leading a paradigm shift in drug development. 2016 , 4, 42	28
2185	High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. 2016 , 4, 67	17
2184	Biochemistry of Oxidative Stress. 2016 ,	3
2183	Overview and management of toxicities of immune checkpoint-blocking drugs. 2016 , 7, 28-37	1
2182	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. 2016 , 1, e000097	59
2181	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. 2016 , 1, 16025	25
2180	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. 2016 , 9, 109	150
2179	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. 2016 , 8, 1363-1369	28
2178	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. 2016 , 8, 1437-1446	19
2177	Immune checkpoint inhibitors renal side effects and management. 2016 , 8, 1417-1425	8
2176	Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. 2016 , 107, 1736-1744	41
2175	Colite induite par les inhibiteurs de checkpoint immunitaire : anticorps anti-CTLA-4 et anticorps anti-PD-1/PDL-1. 2016 , 18, 501-508	1
2174	Immunotherapy in genitourinary malignancies. 2016 , 26, 501-7	5
2173	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. 2016 , 10, 336-342	8
2172	Genitourinary tumours in the targeted therapies era: new advances in clinical practice and future perspectives. 2016 , 27, 917-43	7

2171	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. 2016 , 4, 81	37
2170	Immune Therapy for Prostate Cancer. 2016 , 22, 334-341	10
2169	Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors. 2016 , 39, 367-372	61
2168	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. 2016 , 4, 84	72
2167	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. 2016 , 107, 1730-1735	75
2166	[CCAFU french national guidelines 2016-2018 on renal cancer]. 2016 , 27 Suppl 1, S27-S51	12
2165	Phase 2 Study of Bevacizumab and Temezirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. 2016 , 14, 304-313.e6	10
2164	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. 2016 , 101, 213-20	30
2163	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. 2016 , 5, e1165377	38
2162	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. 2016 , 16, 895-901	15
2161	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. 2016 , 14, 499-503	38
2160	Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. 2016 , 14, e595-e607	4
2159	Ipilimumab and Bevacizumab in Glioblastoma. 2016 , 28, 622-626	52
2158	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. 2016 , 46, 63-72	10
2157	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. 2016 , 62, 36-45	81
2156	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. 2016 , 9, 47	221
2155	Optimizing clinical benefit with targeted treatment in mRCC: "Tumor growth rate" as an alternative clinical endpoint. 2016 , 102, 73-81	3
2154	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. 2016 , 2, 341-342	2

2153	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. 2016 , 8, 681-6	1
2152	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016 , 76, 925-45	100
2151	Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. 2016 , 27, 1706-12	71
2150	Inhibitory immunologiczných punktů kontrolných podziaů komřki w leczeniu chorůb nowotworowych. 2016 , 47, 155-162	1
2149	Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in METastatic RCC (RESUME) Study. 2016 , 62, 28-35	20
2148	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. 2016 , 14, 465-472	51
2147	Targeting T Cell Co-receptors for Cancer Therapy. 2016 , 44, 1069-78	314
2146	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. 2016 , 2, 1179-86	123
2145	Developments in urologic oncology <i>OncoForum</i> —The best of 2015. 2016 , 40, 361-369	
2144	Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells. 2016 , 81, 460-467	13
2143	Local salvage therapy for late (≥ years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. 2016 , 34, 238.e9-17	6
2142	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. 2016 , 76, 3767-72	98
2141	Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. 2016 , 12, 1529-39	6
2140	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). 2016 , 27, 1492-504	280
2139	[Anticancer drugs: Which prices for therapeutic innovations?]. 2016 , 103, 361-7	2
2138	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. 2016 , 352, 189-96	1961
2137	Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 889-90	59.2 21
2136	Recent developments in second and third line therapy of metastatic renal cell carcinoma. 2016 , 16, 469-71	10

2135	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92		335
2134	Developments in urologic oncology «OncoForum»: The best of 2015. 2016 , 40, 361-9		8
2133	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. 2016 , 16, 275-87		1444
2132	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. 2016 , 16, 989-1004		9
2131	The role of neoantigens in response to immune checkpoint blockade. 2016 , 28, 411-9		88
2130	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. 2016 , 18, 601-2		1
2129	Emerging Opportunities and Challenges in Cancer Immunotherapy. 2016 , 22, 1845-55		172
2128	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2542-52	59.2	828
2127	Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. 2016 , 27, 1304-11		50
2126	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. 2016 , 12, 2219-31		33
2125	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. 2016 , 8, 665-74		30
2124	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. 2016 , 8, 583-600		52
2123	[Renaissance of immuno-oncology for urological tumors : Current status]. 2016 , 55, 621-6		2
2122	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. 2016 , 16, 577-84		11
2121	Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors. 2016 , 27, 1356-60		22
2120	Under-reporting of harm in clinical trials. 2016 , 17, e209-19		61
2119	Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. 2016 , 34, 2172-81		95
2118	Emerging therapeutics in refractory renal cell carcinoma. 2016 , 17, 1225-32		12

2117	International cancer seminars: a focus on kidney cancer. 2016 , 27, 1382-5	11
2116	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. 2016 , 22, 5553-5563	70
2115	The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials. 2016 , 12, 2061-3	2
2114	Current Challenges in Cancer Treatment. 2016 , 38, 1551-66	318
2113	[Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. 2016 , 55, 677-90	5
2112	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail. 2016 , 12, 412-20	10
2111	Changing Landscape of Refractory Renal Cell Carcinoma. 2016 , 12, 422-3	
2110	Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. 2016 , 12, 424-5	
2109	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 2016 , 22, 5461-5471	158
2108	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. 2016 , 5, e1151595	39
2107	Perspectives for immunotherapy in endocrine cancer. 2016 , 23, R469-84	10
2106	Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. 2016 , 8, 1163-7	9
2105	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. 2016 , 18, 66	6
2104	First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and network meta-analysis. 2016 , 107, 44-53	22
2103	[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies]. 2016 , 103, 594-603	2
2102	Assessment of Early Tumour Shrinkage: Ready for Integration in the Treatment Strategy for Metastatic Renal Cell Carcinoma?. 2016 , 70, 1016-1018	
2101	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. 2016 , 17, 1590-1598	450
2100	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. 2016 , 3, 268-277	3

2099	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. 2016 , 48, 1327-1329	84
2098	Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. 2016 , 8, 450-459	15
2097	Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?. 2016 , 14, 222	2
2096	Precision medicine from the renal cancer genome. 2016 , 12, 655-666	37
2095	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. 2016 , 50, 208-216	11
2094	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. 2016 , 101, 1144-1158	6
2093	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. 2016 , 16, 744	81
2092	The Advent of Psycho-oncology in Metastatic Renal Cell Carcinoma. 2016 , 2, 650-651	
2091	Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. 2016 , 21, 431-440	6
2090	Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy. 2016 , 34, 3576-3578	24
2089	Immune checkpoint inhibitors: a new class of anticancer drug. 2016 , 27, 23-28	1
2088	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. 2016 , 113, 11919-11924	127
2087	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016 , 27, v58-v68	342
2086	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. 2016 , 50, 109-117	54
2085	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. 2016 , 6, 1382-1399	356
2084	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. 2016 , 16, 1387-1401	16
2083	Les temps forts de Chicago 2016. 2016 , 18, 463-485	
2082	Where next in kidney cancer?. 2016 , 27, 1376-7	

2081	Molecular Imaging of Immunotherapy Targets in Cancer. 2016 , 57, 1487-1492	65
2080	The prospect of precision therapy for renal cell carcinoma. 2016 , 49, 37-44	42
2079	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. 2016 , 12, 2997-3004	9
2078	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. 2016 , 34, 677-684	22
2077	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. 2016 , 63, 1490-1493	156
2076	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. 2016 , 34, 510-518	17
2075	Treatment of head and neck cancer in the elderly. 2016 , 17, 1903-21	11
2074	[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. 2016 , 37, 557-567	31
2073	Pembrolizumab in classical Hodgkin's lymphoma. 2016 , 97, 219-27	16
2072	The immune system and cancer evasion strategies: therapeutic concepts. 2016 , 279, 541-62	146
2071	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. 2016 , 36, 317-34	57
2070	Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection. 2016 , 16, 1332-3	91
2069	Editorial Comment to Pharmacotherapies for renal cell carcinoma in Japan. 2016 , 23, 203	
2068	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. 2016 , 18, 57	17
2067	Medical treatment of renal cancer: new horizons. 2016 , 115, 505-16	56
2066	The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. 2016 , 4, 726-33	85
2065	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. 2016 , 34, 794-796	14
2064	Biennial report on genitourinary cancers. 2016 , 66, 125-30	1

2063	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. 2016 , 27, 1966-9	19
2062	Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. 2016 , 46, 1392-1398	4
2061	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. 2016 , 4, 820-822	44
2060	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. 2016 , 4, 36	76
2059	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). 2016 , 21, 243-54	4
2058	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. 2016 , 12, 1255-61	9
2057	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. 2016 , 76, 5994-6005	136
2056	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. 2016 , 12, 1433-1444	16
2055	Renal cell cancer: overview of the current therapeutic landscape. 2016 , 16, 955-68	15
2054	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. 2016 , 89, 20160472	28
2053	The role of precision medicine for the treatment of metastatic renal cell carcinoma. 2016 , 1, 369-377	2
2052	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. 2016 , 27, 1658-9	3
2051	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. 2016 , 34, 3562-3569	125
2050	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. 2016 , 22, 6051-6060	292
2049	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. 2016 , 34, 538-547	28
2048	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. 2016 , 4, 72	104
2047	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. 2016 , 108, 164-174	93
2046	Perspective: What next for treatment?. 2016 , 537, S111	22

2045	Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs. 2016 , 38, 407-424	
2044	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. 2016 , 9, 939-49	9
2043	Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. 2016 , 311, F424-36	17
2042	Immunotherapy for prostate cancer: False promises or true hope?. 2016 , 122, 3598-3607	19
2041	Loss of IFN- γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. 2016 , 167, 397-404.e9	688
2040	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 , 67, 66-72	79
2039	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. 2016 , 21, 1200-1211	164
2038	Metastasis in renal cell carcinoma: Biology and implications for therapy. 2016 , 3, 286-292	69
2037	Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors. 2016 , 4, 903-909	34
2036	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. 2016 , 8, 460-473	26
2035	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. 2016 , 34, 3740-3748	319
2034	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. 2016 , 17, 1283-94	643
2033	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. 2016 , 12, 1089-96	15
2032	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. 2016 , 70, 705-706	29
2031	Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. 2016 , 12, 2195-204	11
2030	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. 2016 , 8, 785-98	5
2029	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). 2016 , 130, 19-29	71
2028	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. 2016 , 22, 4550-5	55

2027	Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. 2016 , 25, 1326-32	18
2026	Immunotargeting and personalized therapies in genitourinary cancers. 2016 , 12, 1853-6	3
2025	Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. 2016 , 8, 767-74	6
2024	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. 2016 , 16, 1217-1218	2
2023	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. 2016 , 30, 571-584	66
2022	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. 2016 , 1, e000013	31
2021	Immunothérapie et cancer du sein. 2016 , 18, 551-558	2
2020	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. 2016 , 1, e000066	14
2019	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. 2016 , 4, 1038-1048	54
2018	Sunitinib in the treatment of metastatic renal cell carcinoma. 2016 , 8, 348-371	30
2017	PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. 2016 , 5, e1254856	34
2016	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. 2016 , 113, E7759-E7768	234
2015	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. 2016 , 113, E7769-E7777	116
2014	Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. 2016 , 34, 556-565	16
2013	Making urothelial carcinomas less immune to immunotherapy. 2016 , 34, 534-537	1
2012	Cabozantinib for the treatment of renal cell carcinoma. 2016 , 17, 2499-2504	13
2011	A braided cancer river connects tumor heterogeneity and precision medicine. 2016 , 5, 42	7
2010	Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stereotactic Radiotherapy. 2016 , 192, 875-885	14

2009	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. 2016 , 4, 60	46
2008	Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. 2016 , 4, 64	61
2007	Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer. 2016 , 12, 1967-70	
2006	Immunotherapie en onco-urologie. 2016 , 18, 527-532	1
2005	Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1). 2016 , 18, 533-542	2
2004	The tumor microenvironment disarms CD8 T lymphocyte function via a miR-26a-EZH2 axis. 2016 , 5, e1245267	11
2003	Immune checkpoint inhibitors for cancer treatment. 2016 , 39, 1577-1587	29
2002	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. 2016 , 17, 1213-1220	38
2001	Imaging Biomarkers in Immunotherapy. 2016 , 8, 1-13	24
2000	Immunotherapy for Renal Cancer: Sequencing and Combinations. 2016 , 2, 582-588	4
1999	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge-Napoli, December 5th 2015. 2016 , 4,	78
1998	Combination immunotherapy in genitourinary malignancies. 2016 , 26, 523-8	4
1997	Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. 2016 , 4, 34	18
1996	Status quo: Immunotherapie in der Uroonkologie. 2016 , 45, 634-638	
1995	Neue Studienprodukte in der onkologischen Immunotherapie. 2016 , 31, 398-401	
1994	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. 2016 , 2, e000321	33
1993	Immunotherapy in kidney cancer: the past, present, and future. 2016 , 26, 543-7	16
1992	Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma. 2016 , 14, 925-7	1

1991	Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. 2016 , 26, 548-55	7
1990	Cancer immunotherapy: new applications in urologic oncology. 2016 , 26, 535-42	9
1989	Surveillance following surgery for nonmetastatic renal cell carcinoma. 2016 , 26, 432-8	3
1988	Advances in treatment of metastatic renal cell carcinoma. 2016 , 26, 439-46	8
1987	Cancer immunotherapy: new applications in urologic oncology. 2016 , 26, 556-63	4
1986	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. 2016 , 22, 257-66	27
1985	Drug Monographs: Atezolizumab and Everolimus. 2016 , 51, 810-814	0
1984	Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. 2016 , 12, 887-91	
1983	Immunotherapy of Colorectal Cancer. 2016 , 39, 346-50	7
1982	Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. 2016 , 142, 1727-38	56
1981	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. 2016 , 90, 638-47	353
1980	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. 2016 , 76, 4100-12	39
1979	Treatment of elderly patients with advanced urological cancer. 2016 , 9, 20-29	
1978	Literatur kompakt. 2016 , 19, 17-18	
1977	New options in treatment of advanced renal cancer. 2016 , 17, 850-852	1
1976	Impact of genomic sequencing on precision medicine for clinical oncology. 2016 , 1, 255-265	
1975	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. 2016 , 17, 917-927	580
1974	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. 2016 , 17, 994-1003	161

1973	Improved quality of life is the way to longer life. 2016 , 17, 862-863	5
1972	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. 2016 , 9, 411-7	72
1971	Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma. 2016 , 4, 903-908	3
1970	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. 2016 , 48, 20-4	90
1969	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. 2016 , 14, 2476-89	228
1968	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. 2016 , 4, 679-87	54
1967	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). 2016 , 33, 80	27
1966	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. 2016 , 13, 420-31	66
1965	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. 2016 , 28, e127-38	30
1964	Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective. 2016 , 27, 1685-95	40
1963	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. 2016 , 14, 589-98	20
1962	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. 2016 , 43, 501-13	8
1961	Combinatorial approach to cancer immunotherapy: strength in numbers. 2016 , 100, 275-90	65
1960	The best of uro-oncology in 2015. 2016 , 15, 64-64c	
1959	Safety of available treatment options for renal cell carcinoma. 2016 , 15, 1097-106	10
1958	New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer. 2016 , 26, 344-8	15
1957	Brûles de l'ÆRIO. 2016 , 18, 194-197	
1956	Nivolumab verlängert Gesamtüberleben. 2016 , 19, 31-31	

- 1955 Therapieresistentes RCC: Nivolumab verlängert Gesamtüberleben. **2016**, 19, 32-32
- 1954 Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. **2016**, 58, 49-51
- 1953 Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. **2016**, 140, 501-2 10
- 1952 Genomic determinants of cancer immunotherapy. **2016**, 41, 32-38 20
- 1951 Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. **2016**, 57, 1607-1611 84
- 1950 Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma. **2016**, 14, e431-4 18
- 1949 Immune Checkpoint Inhibitors in Older Adults. **2016**, 18, 47 40
- 1948 Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma. **2016**, 22, 5839-5850 20
- 1947 Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. **2016**, 39, 353-8 5
- 1946 Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. **2016**, 27, 1579-85 30
- 1945 Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?. **2016**, 122, 1966-70 5
- 1944 PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. **2016**, 139, 396-403 113
- 1943 Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. **2016**, 13, 442-3 7
- 1942 Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. **2016**, 65, 941-9 15
- 1941 [Cancer immunotherapy: Rational and recent breakthroughs]. **2016**, 37, 694-700 22
- 1940 Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?. **2016**, 12, 429-31 2
- 1939 Axitinib for the treatment of metastatic renal cell carcinoma. **2016**, 12, 303-11 5
- 1938 Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma. **2016**, 12, 277-9

1937	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. 2016 , 32, 741-7	11
1936	The promising role of nivolumab in renal cell cancers. 2016 , 17, 123-4	6
1935	Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma. 2016 , 89, 8-9	6
1934	[Update 2016 - Immunotherapy for urothelial carcinoma]. 2016 , 55, 246-52	
1933	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. 2016 , 12, 57-75	39
1932	2015 and human cancer: back to overall survival. 2016 , 12, 1751-4	
1931	Hypoxia-inducible Factor Crosses the Checkpoint. 2016 , 70, 633-634	1
1930	Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?. 2016 , 69, 969-70	3
1929	Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. 2016 , 99, 324-31	11
1928	Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. 2016 , 14, 153-9	10
1927	Words of Wisdom. Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. 2016 , 69, 538-9	2
1926	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. 2016 , 20, 175-81	26
1925	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2016 , 34, 987-1011	114
1924	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. 2016 , 45, 7-18	264
1923	Evolving treatment landscape in metastatic renal cell carcinoma: where are we now?. 2016 , 16, 133-5	1
1922	Management of toxicities of immune checkpoint inhibitors. 2016 , 44, 51-60	522
1921	A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. 2016 , 16, 605-18	12
1920	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190

1919	Coinhibitory Pathways in Immunotherapy for Cancer. 2016 , 34, 539-73	507
1918	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. 2016 , 70, 358-64	112
1917	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. 2016 , 34, 171-81	31
1916	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. 2016 , 387, 1909-20	2308
1915	Reply to Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. 2016 , 70, e75-6	
1914	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. 2016 , 70, e72-4	5
1913	Emerging immunotherapy for the treatment of esophageal cancer. 2016 , 25, 667-77	21
1912	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358
1911	A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). 2016 , 27, 880-6	11
1910	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. 2016 , 22, 2102-4	26
1909	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2016 , 10, 183-93	90
1908	Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. 2016 , 45, 30-7	168
1907	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. 2016 , 5, e1108511	23
1906	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. 2016 , 27, 559-74	548
1905	Prospects for gene-engineered T cell immunotherapy for solid cancers. 2016 , 22, 26-36	243
1904	Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). 2016 , 27, 441-8	28
1903	Prospects for the use of ipilimumab in treating advanced prostate cancer. 2016 , 16, 421-32	5
1902	Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. 2016 , 27, 544-5	12

1901	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. 2016 , 17, 643-55	9
1900	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. 2016 , 69, 4-6	68
1899	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. 2017 , 71, 204-209	52
1898	Systemic therapy in metastatic renal cell carcinoma. 2017 , 35, 179-188	88
1897	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. 2017 , 24, 111-120	14
1896	Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma. 2017 , 72, 12-18	20
1895	PD-L1, Galectin-9 and CD8 tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. 2017 , 6, e1273309	93
1894	Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. 2017 , 29, 245-251	19
1893	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. 2017 , 18, 205-216	5
1892	Strategies to overcome therapeutic resistance in renal cell carcinoma. 2017 , 35, 102-110	26
1891	The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. 2017 , 17, 217-226	4
1890	Immunotherapy for Prostate Cancer Why Now?. 2017 , 4, 329-334	0
1889	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759	50
1888	Immunomodulatory Activity of VEGF in Cancer. 2017 , 330, 295-342	95
1887	[Which recent results in Oncology and Hematology will have an impact on our practices? The point of view of Bulletin du Cancer editorial board]. 2017 , 104, 6-19	0
1886	Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. 2017 , 15, e517-e519	4
1885	First-Line Pazopanib in Non-clear-cell Renal Carcinoma: The Italian Retrospective Multicenter PANORAMA Study. 2017 , 15, e609-e614	30
1884	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 2017 , 110, 106-116	29

1883	Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit. 2017 , 53, 53-60	7
1882	Renal complications of immune checkpoint blockade. 2017 , 41, 100-110	61
1881	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. 2017 , 3, 502-509	18
1880	Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8. 2017 , 71, e177-e178	
1879	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. 2017 , 73, 1-8	279
1878	Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. 2017 , 14, 82-84	4
1877	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. 2017 , 47, 226-232	7
1876	Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. 2017 , 53, 111-119	97
1875	Checkpoint inhibition: new treatment options in urologic cancer. 2017 , 72, 24-28	8
1874	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. 2017 , 17, 357-368	6
1873	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. 2017 , 15, 1	116
1872	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. 2017 , 35, 1401-1407	26
1871	Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. 2017 , 58, 905-910	38
1870	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. 2017 , 18, 312-322	981
1869	Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 354-366	641
1868	Cardiovascular Toxicities Associated with Cancer Immunotherapies. 2017 , 19, 21	99
1867	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. 2017 , 37, 46-54	1
1866	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 17, 387-394	89

1865	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. 2017 , 6, e1286437	21
1864	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. 2017 , 23, 4270-4279	84
1863	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. 2017 , 25, 1713-1739	82
1862	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. 2017 , 8, 229-235	71
1861	Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. 2017 , 10, 251-262	3
1860	Targeting neoantigens to augment antitumour immunity. 2017 , 17, 209-222	449
1859	Patient-derived xenografts as in vivo models for research in urological malignancies. 2017 , 14, 267-283	49
1858	Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. 2017 , 125, 259-263	14
1857	Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. 2017 , 5, 1	37
1856	[Immunotherapy in uropathology]. 2017 , 37, 90-100	
1855	PD-1 and PD-L1 antibodies in cancer: current status and future directions. 2017 , 66, 551-564	188
1854	[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives]. 2017 , 37, 133-141	
1853	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. 2017 , 15, 403-410.e2	12
1852	Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. 2017 , 15, e675-e680	3
1851	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1015-1026	59.2 1788
1850	Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. 2017 , 6, e1274476	28
1849	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. 2017 , 18, 7	40
1848	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. 2017 , 18, 446-453	223

1847	MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. 2017 , 6, e1280645	15
1846	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. 2017 , 7, 44173	50
1845	Renal cell carcinoma. 2017 , 3, 17009	963
1844	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. 2017 , 13, 1097-1103	1
1843	[Pulmonary metastasectomy in renal cell carcinoma]. 2017 , 56, 1025-1030	2
1842	FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. 2017 , 22, 311-317	43
1841	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. 2017 , 9, 261-272	24
1840	[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives]. 2017 , 104, 370-379	0
1839	Candidate immune biomarkers for radioimmunotherapy. 2017 , 1868, 58-68	13
1838	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. 2017 , 5, 312-318	259
1837	Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. 2017 , 19, 14	36
1836	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. 2017 , 18, e143-e152	1010
1835	New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. 2017 , 10, 38	50
1834	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. 2017 , 8, 14369	128
1833	Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. 2017 , 15, 5	23
1832	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. 2017 , 12, 44-50	10
1831	DNA vaccines for prostate cancer. 2017 , 174, 27-42	25
1830	Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. 2017 , 35, 363-369	13

1829	Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. 2017 , 101, 657-666	89
1828	Designing nanomedicine for immuno-oncology. 2017 , 1,	138
1827	Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. 2017 , 24, 272-278	13
1826	The CD47-SIRPβ signaling axis as an innate immune checkpoint in cancer. 2017 , 276, 145-164	225
1825	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. 2017 , 14, 1049-1065	15
1824	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. 2017 , 72, 962-971	136
1823	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. 2017 , 6, e1269047	35
1822	Developing a model for embedded palliative care in a cancer clinic. 2017 , 7, 247-250	3
1821	Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. 2017 , 35, 142-148	12
1820	HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. 2017 , 6, e1293214	19
1819	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. 2017 , 76, 1-7	38
1818	The expanding role of immunotherapy. 2017 , 54, 74-86	72
1817	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. 2017 , 162, 479-488	10
1816	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. 2017 , 98, 344-351	107
1815	What advances have been made in immune-therapy for renal cell carcinoma?. 2017 , 13, 665-668	
1814	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. 2017 , 18, 255-262	260
1813	Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab. 2017 , 8, 175-180	4
1812	Pembrolizumab in recurrent advanced cervical squamous carcinoma. 2017 , 9, 467-470	10

1811	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. 2017 , 20, 205-215	52
1810	Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. 2017 , 15, 652-660.e1	21
1809	[Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell Carcinoma]. 2017 , 48, 72-78	1
1808	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. 2017 , 389, 2492-2502	2151
1807	Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. 2017 , 47, 639-646	43
1806	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. 2017 , 141, 851-861	64
1805	Metastatic soft tissue sarcoma: current treatment landscape and future perspectives. 2017 , 17, 537-543	9
1804	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. 2017 , 34, 99	14
1803	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 2017 , 9, 34	1509
1802	Renal cell carcinoma: molecular characterization and evolving treatment paradigms. 2017 , 29, 201-209	7
1801	Nivolumab induced myxedema crisis. 2017 , 5, 13	34
1800	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. 2017 , 72, 368-376	148
1799	Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy. 2017 , 19, 1175-1182	17
1798	WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. 2017 ,	
1797	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. 2017 , 72, 557-564	81
1796	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. 2017 , 41, 643-654	98
1795	Setting Research Priorities for Kidney Cancer. 2017 , 72, 861-864	15
1794	Osteoporosis Rehabilitation. 2017 ,	2

1793	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. 2017 , 29, 17-22	17
1792	Immunotherapy for metastatic renal cell carcinoma. 2017 , 5, CD011673	19
1791	[Cancer, radiotherapy and immune system]. 2017 , 21, 307-315	8
1790	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. 2017 , 79, 185-192	18
1789	Metastatic Renal Cell Carcinoma to Jejunum: An Unusual Case Presentation. 2017 , 13, 34-36	3
1788	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. 2017 , 9, 287-298	4
1787	Emerging therapies for breast cancer. 2017 , 10, 98	37
1786	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. 2017 , 13, 1765-1767	2
1785	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. 2017 , 77, 3540-3550	213
1784	Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. 2017 , 13, 1323-1332	2
1783	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. 2017 , 17, 50	6
1782	RECISTing the Temptation to Prematurely Stop Nivolumab. 2017 , 72, 377-378	
1781	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. 2017 , 12, 763-769	105
1780	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. 2017 , 6, e1320626	47
1779	Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. 2017 , 28, 1996-2001	150
1778	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. 2017 , 77, 2318-2327	153
1777	Immunotherapy in genitourinary malignancies. 2017 , 10, 95	25
1776	Programmed cell death ligand 1 as a biomarker in head and neck cancer. 2017 , 125, 529-533	1

1775	Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence. 2017 , 35, 665-668	13
1774	Palliative and End-of-Life Care for Patients with Malignancy. 2017 , 38, 363-376	12
1773	Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. 2017 , 28, 1339-1345	63
1772	Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. 2017 , 28, 1605-1611	324
1771	Trends in Scientific Discovery. 2017 , 31-64	
1770	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. 2017 , 123, 3285-3290	106
1769	Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. 2017 , 15, 582-590	23
1768	A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). 2017 , 15, 642-651.e1	0
1767	Dysfunctional T cell metabolism in the tumor microenvironment. 2017 , 35, 7-14	59
1766	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. 2017 , 23, 138-143	24
1765	Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?. 2017 , 13, 381-383	3
1764	Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. 2017 , 24, 1435-1442	24
1763	Advances in urology 2015-2016. 2017 , 10, 39-48	
1762	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 2017 , 18, 31-41	605
1761	Percutaneous biopsy in large, locally advanced or metastatic renal tumors. 2017 , 35, 87-91	5
1760	A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer. 2017 , 22, 784-e74	1
1759	[Immunotherapy in urothelial carcinoma from a pathologist's perspective]. 2017 , 48, 336-339	
1758	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. 2017 , 81, 116-129	314

1757	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. 2017 , 6, 131-134	2
1756	PD-L1 Expression in Pancreatic Cancer. 2017 , 109,	26
1755	Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. 2017 , 39, 1010428317705514	8
1754	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. 2017 , 57, 36-49	185
1753	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. 2017 , 22, 963-971	96
1752	Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. 2017 , 28, 2002-2008	108
1751	The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. 2017 , 13, 1463-1471	2
1750	Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. 2017 , 7, 1030-1045	23
1749	Advancing Immunotherapy in Metastatic Breast Cancer. 2017 , 18, 35	12
1748	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. 2017 , 102, 2770-2780	125
1747	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. 2017 , 22, 667-679	50
1746	Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT. 2017 , 7, 396-399	12
1745	A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. 2017 , 23, 5055-5065	31
1744	Clinical development of immunotherapy for prostate cancer. 2017 , 24, 675-680	5
1743	Recent progress in immunotherapy for urological cancer. 2017 , 24, 735-742	12
1742	Cabozantinib for the treatment of kidney cancer. 2017 , 17, 577-584	25
1741	Stereotactic Body Radiotherapy. 2017 , 323-395	
1740	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. 2017 , 12, 301-308	47

1739 Milestones in advanced renal cell carcinoma. **2017**, 10, 38-41

1738 Evolving adoptive cellular therapies in urological malignancies. **2017**, 18, e341-e353 16

1737 Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. **2017**, 81, 9-16 10

1736 Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. **2017**, 198, 1027-1032 2

1735 Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated F-Fluorodeoxyglucose (F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. **2017**, 17, 392 11

1734 Immunological effect of local ablation combined with immunotherapy on solid malignancies. **2017**, 36, 49 16

1733 Integrating Immunotherapy Into the Management of Renal Cell Carcinoma. **2017**, 15, 841-847 5

1732 Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. **2017**, 38, 577-593 190

1731 The potential of organoids in urological cancer research. **2017**, 14, 401-414 51

1730 PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. **2017**, 7, 2074 14

1729 A case of cystitis after administration of nivolumab. **2017**, 6, 164-166 9

1728 Combining radiotherapy with immunotherapy: the past, the present and the future. **2017**, 90, 20170157 60

1727 Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. **2017**, 16, 1705-1717 36

1726 Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. **2017**, 99, 153-164 52

1725 Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. **2017**, 23, 869-877 71

1724 Incorporating New Systemic Therapies in Kidney Cancer Treatment. **2017**, 15, 703-705 4

1723 Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. **2017**, 10, 511-517 27

1722 Personalized peptide vaccines and their relation to other therapies in urological cancer. **2017**, 14, 501-510 20

1721	Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. 2017 , 12, 487-494	23
1720	Future perspectives for personalized immunotherapy in renal cell carcinoma. 2017 , 17, 1049-1052	11
1719	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. 2017 , 9, 579-587	10
1718	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. 2017 , 28, 1988-1995	210
1717	Current management of metastatic renal cell carcinoma: evolving new therapies. 2017 , 11, 231-237	11
1716	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. 2017 , 22, 627-630	49
1715	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. 2017 , 17, 647-655	10
1714	Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. 2017 , 9, 375-378	2
1713	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62	38
1712	Promising immunotherapies for esophageal cancer. 2017 , 17, 723-733	16
1711	Combination of Antiangiogenics and Other Targeted Therapies. 2017 , 1-18	1
1710	Case report of nivolumab-related pneumonitis. 2017 , 9, 313-318	5
1709	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669	92
1708	Cancer immunotherapies targeting the PD-1 signaling pathway. 2017 , 24, 26	332
1707	Biomarkers to predict prognosis and response to checkpoint inhibitors. 2017 , 22, 629-634	39
1706	Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. 2017 , 28, 1484-1494	81
1705	Renal cell carcinoma: new insights and challenges for a clinician scientist. 2017 , 313, F145-F154	28
1704	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. 2017 , 34, 331-357	6

1703	Nivolumab in renal cell carcinoma: latest evidence and clinical potential. 2017 , 9, 171-181	42
1702	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. 2017 , 31, 476-485	86
1701	Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619	26
1700	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. 2017 , 20, 185-204	309
1699	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. 2017 , 9, 423-433	6
1698	Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms. 2017 , 18, 18	12
1697	Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. 2017 , 18, 631-639	247
1696	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. 2017 , 5, 8	86
1695	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. 2017 , 178, 31-47	58
1694	Neoadjuvant Targeted Molecular Therapy Before Renal Surgery. 2017 , 44, 289-303	2
1693	Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. 2017 , 19, 27	15
1692	Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?. 2017 , 72, 972-973	
1691	Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives. 2017 , 123, 2634-2641	35
1690	Nivolumab in previously treated patients with advanced renal cell carcinoma: a guide to its use. 2017 , 33, 167-173	
1689	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. 2017 , 113, 171-190	14
1688	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. 2017 , 76, 167-182	182
1687	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. 2017 , 17, 735-746	36
1686	Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy. 2017 , 19, 531-537	1

1685	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. 2017 , 27, 289-298	28
1684	Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. 2017 , 5, 376-384	63
1683	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. 2017 , 129, 275-279	67
1682	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. 2017 , 18, 52-62	164
1681	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. 2017 , 140, 2535-2544	30
1680	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. 2017 , 389, 67-76	1171
1679	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. 2017 , 28, 583-589	348
1678	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. 2017 , 9, 5-8	18
1677	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138	16
1676	Atypical autoimmune adverse effects with checkpoint blockade therapies. 2017 , 28, 206-207	11
1675	What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?. 2017 , 18, 1-4	1
1674	Molecular approaches for classifying endometrial carcinoma. 2017 , 145, 200-207	88
1673	Biomarkers of Renal Cancer. 2017 , 421-467	1
1672	Current Trends in Cancer Therapy. 2017 , 1-24	3
1671	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. 2017 , 29, 218-230	37
1670	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM. 2017 , 15, 31-41.e4	28
1669	Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. 2017 , 487, 1-7	25
1668	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. 2017 , 49, 141-155	68

1667	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. 2017 , 16, 264-272	127
1666	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. 2017 , 76, 43-50	248
1665	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. 2017 , 16, 319-327	7
1664	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. 2017 , 69, 1751-1763	216
1663	Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. 2017 , 77, 17-28	8
1662	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. 2017 , 6, e1257452	106
1661	Emerging biomarkers for PD-1 pathway cancer therapy. 2017 , 11, 53-67	9
1660	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. 2017 , 17, 151-162	4
1659	Innate immune signaling and regulation in cancer immunotherapy. 2017 , 27, 96-108	205
1658	The clinical development of vaccines for HER2 breast cancer: Current landscape and future perspectives. 2017 , 61, 107-115	21
1657	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. 2017 , 16, 301-308	4
1656	Sepsis: Staging and Potential Future Therapies. 2017 , 9, i-91	
1655	Treatment of renal cell carcinoma: Current status and future directions. 2017 , 67, 507-524	321
1654	Multimodal treatment of advanced renal cancer in 2017. 2017 , 10, 1395-1402	19
1653	Adjuvant therapy in renal cell carcinoma. 2017 , 60, 152-157	25
1652	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. 2017 , 2, e000236	19
1651	[MiR-140-3p Downregulation in Association with PDL-1 Overexpression in Many Cancers: A Review from the Literature Using Predictive Bioinformatics Tools]. 2017 , 988, 225-233	15
1650	Immune checkpoint inhibitors in renal cell carcinoma. 2017 , 131, 2627-2642	38

1649	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. 2017 , 9, 995-1004	10
1648	Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!. 2017 , 16, 241-252	1
1647	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017 , 390, 2461-2471	1123
1646	c-Jun N-terminal kinase in pancreatic tumor stroma augments tumor development in mice. 2017 , 108, 2156-2165	12
1645	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). 2017 , 23, 7199-7208	57
1644	4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. 2017 , 23, 7263-7275	29
1643	Clinical development of mTor inhibitors for renal cancer. 2017 , 26, 1229-1237	37
1642	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. 2017 , 119, 1-12	105
1641	Immunological effects of everolimus in patients with metastatic renal cell cancer. 2017 , 30, 341-352	17
1640	Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. 2017 , 9, 627-636	8
1639	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. 2017 , 171, 934-949.e16	831
1638	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205	13
1637	Racial/ethnic disparities: need more work!. 2017 , 130, 1685-1686	2
1636	Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. 2017 , 119, 23-28	12
1635	Mechanisms regulating T-cell infiltration and activity in solid tumors. 2017 , 28, xii18-xii32	175
1634	Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. 2017 , 47, 1170-1174	2
1633	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017 , 86, 257-265	21
1632	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. 2017 , 28, 2860-2865	71

1631	Checkpoint immunotherapy in head and neck cancers. 2017 , 36, 475-489	27
1630	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. 2017 , 16, 2598-2608	1183
1629	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). 2017 , 84, 212-218	78
1628	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 2017 , 18, 1477-1490	16
1627	Nivolumab-associated nausea and vomiting as an immune adverse event. 2017 , 84, 367-369	7
1626	[Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with Nivolumab]. 2017 , 38, 535-539	8
1625	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). 2017 , 84, 202-211	25
1624	Angiogenic, inflammatory and immunologic markers in predicting response to sunitinib in metastatic renal cell carcinoma. 2017 , 108, 1858-1863	14
1623	Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?. 2017 , 27, 566-571	9
1622	CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. 2017 , 117, 947-953	14
1621	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. 2017 , 117, 913-920	111
1620	Tumour radiosensitivity is associated with immune activation in solid tumours. 2017 , 84, 304-314	27
1619	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
1618	Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. 2017 , 23, 5394-5405	48
1617	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. 2017 , 57 Suppl 10, S26-S42	63
1616	Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. 2017 , 16, 1413-1426	2
1615	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. 2017 , 85, 39-48	2
1614	Évaluation thérapeutique des tumeurs solides Session 6. 2017 , 41, 367-370	

1613	Second-line systemic therapy in metastatic renal-cell carcinoma: A review. 2017 , 35, 640-646	11
1612	Emerging immunotherapy in advanced renal cell carcinoma. 2017 , 35, 687-693	10
1611	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. 2017 , 60, 60-68	83
1610	Duodenal metastases from sarcomatoid renal cell carcinoma: Case report. 2017 , 40, 530-532	
1609	PD-1 checkpoint inhibition: Toxicities and management. 2017 , 35, 701-707	44
1608	Systemic treatment of renal cell cancer: A comprehensive review. 2017 , 60, 77-89	81
1607	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. 2017 , 56, 5428-5439	15
1606	Role of PD-1 in Immunity and Diseases. 2017 , 410, 75-97	85
1605	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. 2017 , 49, 2143-2149	25
1604	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. 2017 , 12, 1626-1635	55
1603	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. 2017 , 23, 4980-4991	12
1602	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. 2017 , 23, 4959-4969	71
1601	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. 2017 , 23, 4992-5002	26
1600	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. 2017 , 73, 138-146	61
1599	Imaging strategy and outcome following partial nephrectomy. 2017 , 35, 660.e1-660.e8	6
1598	[Immunotherapy as modern tumor treatment]. 2017 , 57, 822-825	3
1597	[Immunotherapy: Activation of a system not a pathway]. 2017 , 104, 462-475	
1596	Immunotherapy in genitourinary cancers: where are we going?. 2017 , 2, 73-78	2

- 1595 Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine. **2017**, 284, 333-351 33
- 1594 Racial and ethnic disparities in hematologic malignancies. **2017**, 130, 1699-1705 60
- 1593 [Cabozantinib: Mechanism of action, efficacy and indications]. **2017**, 104, 393-401 14
- 1592 Cancer Immunotherapy in Older Patients. **2017**, 23, 219-222 14
- 1591 New treatment options for metastatic renal cell carcinoma. **2017**, 2, e000185 49
- 1590 Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. **2017**, 59, 71-78 65
- 1589 Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. **2017**, 35, 603.e7-603.e14
- 1588 A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. **2017**, 6, 1904-1914 13
- 1587 Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. **2017**, 22, 1081-1086 20
- 1586 Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. **2017**, 11, 1238-1246 79
- 1585 Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. **2017**, 13, 277-288 31
- 1584 PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. **2017**, 152, 357-371 85
- 1583 Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. **2017**, 44, 132-135 64
- 1582 First-line vascular endothelial growth factor inhibitors for advanced renal cell carcinoma and the impact of new agents entering the treatment paradigm. **2017**, 120, 749-751 1
- 1581 Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. **2017**, 108, 1223-1230 47
- 1580 Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. **2017**, 83, 28-31 27
- 1579 Câncer renal. **2017**, 12, 1947-1954
- 1578 Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. **2017**, 141, 1891-1900 20

1577	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
1576	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. 2017 , 15, e897-e901	12
1575	Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients. 2017 , 19, 22-26	2
1574	Immunotherapy: Who Is Eligible?. 2017 , 50, 867-874	4
1573	Clinical and palliative care outcomes for patients of poor performance status treated with anti-programmed death-1 monoclonal antibodies for advanced melanoma. 2017 , 13, 385-390	24
1572	Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. 2017 , 34, 149	7
1571	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. 2017 , 58, 446-455	32
1570	Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis. 2017 , 72, 1027-1028	0
1569	Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. 2017 , 14, 753-759	11
1568	Checkpoint inhibitors in the treatment of urological malignancies. 2017 , 2, e000165	15
1567	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. 2017 , 83, 237-246	20
1566	Current management of renal cell cancer. 2017 , 8, 21-25	1
1565	Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma. 2017 , 52, 103-110	13
1564	The importance for immunoregulation for long-term cancer control. 2017 , 13, 1619-1632	8
1563	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. 2017 , 117, 921-924	52
1562	Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. 2017 , 13, 1839-1852	4
1561	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. 2017 , 44, 2310-2325	34
1560	[The breakthrough of personalized medicine, new hopes and new challenges]. 2017 , 104, 735-743	1

1559	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. 2017 , 549, 106-110	309
1558	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. 2017 , 15, e1081-e1088	6
1557	Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. 2017 , 41, 1381-1389	44
1556	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. 2017 , 19, 64	71
1555	Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma. 2017 , 57, 1527-1533	22
1554	Recent developments in small molecule therapies for renal cell carcinoma. 2017 , 142, 383-392	20
1553	Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment. 2017 , 24, 708-710	27
1552	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. 2017 , 6, e1346764	37
1551	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Metastatic Tumors. 2017 , 24, 311-335	299
1550	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. 2017 , 24, 235-251	293
1549	Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. 2017 , 6, e1349587	36
1548	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. 2017 , 18, 51	56
1547	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. 2017 , 28, 2377-2385	372
1546	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. 2017 , 11, 1178223417731565	25
1545	Immunotherapy of Cancer. 2017 , 244-266	
1544	The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies. 2017 , 11, 1149-1159	6
1543	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel -Activating Mutation. 2017 , 15, 1310-1315	13
1542	Examining the bleeding incidences associated with targeted therapies used in metastatic renal cell carcinoma. 2017 , 120, 151-162	11

1541	Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety. 2017 , 13, 2709-2717	5
1540	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. 2017 , 8, 1751	300
1539	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. 2017 ,	0
1538	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2
1537	Targeting immune checkpoints in breast cancer: an update of early results. 2017 , 2, e000255	79
1536	De-novo and acquired resistance to immune checkpoint targeting. 2017 , 18, e731-e741	383
1535	Immunotherapie urologischer Tumoren. 2017 , 20, 28-35	
1534	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. 2017 , 22, 1470-1477	7
1533	Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma. 2017 , 1-17	1
1532	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. 2017 , 13, 755-763	95
1531	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression. 2017 , 3, 268-278	13
1530	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. 2017 , 18, 1104-1115	232
1529	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. 2017 , 19, 49	15
1528	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. 2017 , 403, 159-164	32
1527	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. 2017 , 72, 411-423	61
1526	High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. 2017 , 51, 367-372	9
1525	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. 2017 , 23, 10-22	35
1524	Nivolumab ist eine neue Therapieoption beim metastasierten Nierenzellkarzinom. 2017 , 23, 232-233	

1523 Checkpointinhibitoren. **2017**, 23, 619-625

1522 Immune checkpoint inhibitors and elderly people: A review. **2017**, 82, 155-166

99

1521 Targeted therapies for renal cell carcinoma. **2017**, 13, 496-511

127

1520 Intratumor heterogeneity of immune checkpoints in primary renal cell cancer: Focus on HLA-G/ILT2/ILT4. **2017**, 6, e1342023

24

1519 Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. **2017**, 23, 5187-5201

211

1518 A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma. **2017**, 22, 888-e84

2

1517 Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. **2017**, 18, 1009-1021

492

1516 Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. **2017**, 35, 1807-1816

7

1515 Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. **2017**, 28, iv119-iv142

1100

1514 Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma. **2017**, 15, e1127-e1130

14

1513 A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. **2017**, 44, 136-140

119

1512 PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. **2017**, 66, 13-33

34

1511 Biomarkers of response to PD-1/PD-L1 inhibition. **2017**, 116, 116-124

185

1510 Systemische Therapie des metastasierten Nierenzellkarzinoms. **2017**, 20, 31-40

1509 Neuer Tyrosinkinaseinhibitor für die Zweitlinie. **2017**, 20, 12-14

1508 Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial. **2017**, 5, 75-78

5

1507 Monitoring immune-checkpoint blockade: response evaluation and biomarker development. **2017**, 14, 655-668

498

1506 The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. **2017**, 2, 169-175

8

1505	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. 2017 , 198, 1253-1262	41
1504	Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. 2017 , 5, 31	35
1503	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. 2017 , 5, 46	49
1502	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. 2017 , 5, 49	20
1501	Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. 2017 , 5, 52	33
1500	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. 2017 , 22, 1232-1237	87
1499	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. 2017 , 9, 681-692	69
1498	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. 2017 , 36, 5-15	33
1497	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. 2017 , 124, 98-103	43
1496	Immunotherapeutic Approaches to Biliary Cancer. 2017 , 18, 44	8
1495	A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. 2017 , 18, 547-551	31
1494	Immunchekpointinhibitoren. 2017 , 23, 575-584	
1493	PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. 2017 , 14, 203-220	250
1492	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. 2017 , 23, 1920-1928	698
1491	The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. 2017 , 29, 153-160	39
1490	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4. 2017 , 71, e27-e28	0
1489	Duodenal metastases from sarcomatoid renal cell carcinoma: Case report. 2017 , 40, 530-532	1
1488	Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?. 2017 , 123, 200-209	22

1487	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. 2017 , 12, 19-35	57
1486	Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. 2017 , 23, 342-350	34
1485	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. 2017 , 18, 35-44	16
1484	Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. 2017 , 38, 25-40	62
1483	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. 2017 , 44, 158-176	135
1482	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 2017 , 28, 57-74	32
1481	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. 2017 , 71, 970-978	12
1480	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. 2017 , 30, 278-285	59
1479	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. 2017 , 140, 948-958	33
1478	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. 2017 , 13, 528-532	23
1477	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. 2017 , 17, 135-149	4
1476	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. 2017 , 18, 132-140	15
1475	Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?. 2017 , 14, 85-99	125
1474	Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. 2017 , 35, 641-648	10
1473	Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. 2017 , 44, 117-122	121
1472	Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. 2017 , 197, 44-49	69
1471	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. 2017 , 35, 35.e1-35.e5	18
1470	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. 2017 , 71, 237-246	41

1469	Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features. 2017 , 15, 7-22	1
1468	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. 2017 , 64, 98-106	37
1467	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. 2017 , 12, 176-189	28
1466	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. 2017 , 20, 602-611	53
1465	Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review. 2017 , 2, 108-123	42
1464	Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. 2017 , 71, 210-212	1
1463	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. 2017 , 12, 194-207	132
1462	Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. 2017 , 15, e165-e167	1
1461	Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. 2017 , 28, 44-56	24
1460	OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. 2017 , 91, 175-179	11
1459	Management of Adrenal Masses in Children and Adults. 2017 ,	4
1458	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. 2017 , 77, 123-144	4
1457	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. 2017 , 28, 368-376	468
1456	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. 2017 , 100, 139-144	5
1455	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCulating Endothelial cells) Study (SOGUG-CEC-2011-01). 2017 , 3, 430-436	3
1454	A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma. 2017 , 123, 576-582	27
1453	Re: Francesco Piva, Matteo Santoni, Marina Scarpelli, et al's Letter to the Editor re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. 2017 , 71, e26	1
1452	PD-1/PD-L1 blockade in renal cell cancer. 2017 , 13, 77-84	24

1451	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. 2017 , 62, 397-405	31
1450	Immunotherapy approaches in the treatment of malignant brain tumors. 2017 , 123, 734-750	63
1449	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. 2017 , 34, 8-19	15
1448	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. 2017 , 35, 591-597	434
1447	Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. 2017 , 43, 65-78	78
1446	Metastatic Anal Cancer and Novel Agents. 2017 , 26, 133-142	6
1445	Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. 2017 , 20, 407-415	130
1444	Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. 2017 , 140, 142-148	33
1443	Biomarkers in Genitourinary Cancers: Blazing the Path Forward. 2017 , 71, 247-248	2
1442	Wnt signaling in cancer. 2017 , 36, 1461-1473	1238
1441	Current Role of Radiotherapy for Renal-Cell Carcinoma: Review. 2017 , 15, 183-187	14
1440	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. 2017 , 35, 709-717	587
1439	Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion. 2017 , 136, 49-51	54
1438	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. 2017 , 109,	104
1437	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017 , 96, e8931	17
1436	Novel concepts of antiangiogenic therapies in metastatic renal cell cancer. 2017 , 10, 206-212	8
1435	Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. 2017 , 1, 65-70	25
1434	Immunotherapy in the Elderly. 2017 , 3, 403-412	12

1433	Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus. 2017 , 5, 1950-1953	2
1432	Informatics for cancer immunotherapy. 2017 , 28, xii56-xii73	11
1431	Les complications de l'immunothérapie. 2017 , 9, 325-331	1
1430	Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report. 2017 , 7, 988-990	12
1429	Molecular Heterogeneity of Renal Cell Carcinoma. 2017 , 1-8	
1428	Metastatic Surgery in Advanced Renal Cell Carcinoma. 2017 , 1-26	
1427	Management immunvermittelter Nebenwirkungen. 2017 , 20, 54-64	
1426	Targeted therapy for metastatic renal cell carcinoma. 2017 ,	4
1425	Immuntherapie in der Onkologie. 2017 , 12, 17-33	1
1424	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. 2017 , 37, 319-329	15
1423	Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms. 2017 , 38, 373-380	
1422	Genomic Profiling to Expand Management Options for Locally Advanced Esophagogastric Cancers: A Proof of Principle Case. 2017 , 1,	0
1421	The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians. 2017 , 11, 379-387	21
1420	RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB. 2017 , 23, 1223-1231	16
1419	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	4
1418	Clinical use of immune checkpoint inhibitors. 2017 ,	
1417	Treatment of kidney cancer: Oncological approach. 2017 , 53, 359-364	
1416	Appendix 1: Renal cell carcinoma: MCBS eUpdate published online 10 April 2017(www.esmo.org/Guidelines/Genitourinary-Cancers). 2017 , 28, iv143-iv144	

1415	High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. 2017 , 1, 1306-1308	16
1414	[Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management]. 2017 , 158, 1488-1502	2
1413	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. 2017 , 8, 730	233
1412	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. 2017 , 8, 410-416	115
1411	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. 2017 , 13, 1259-1271	12
1410	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. 2017 , 10, 2097-2106	32
1409	Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets. 2017 , 18,	18
1408	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
1407	Immunotherapy Clinical Trials in Neuro-Oncology. 2017 , 181-210	
1406	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. 2017 , 7, 1-11	29
1405	Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. 2017 , 18,	12
1404	MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review. 2017 , 18,	30
1403	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. 2017 , 18,	60
1402	Novel immunotherapy in metastatic renal cell carcinoma. 2017 , 58, 220-227	13
1401	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. 2017 , 18,	43
1400	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. 2017 , 18,	22
1399	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. 2017 , 18,	122
1398	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145

1397	Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: A multicentre study in Korea. 2018 , 12, E15-E20	2
1396	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. 2017 , 7, 3585-3594	127
1395	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. 2017 , 8, 418-429	18
1394	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. 2017 , 8, 267	47
1393	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. 2017 , 8, 961	70
1392	Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. 2017 , 7, 56	54
1391	Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. 2017 , 7, 107	30
1390	Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. 2017 , 7, 114	17
1389	Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma. 2017 , 7, 141	14
1388	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. 2017 , 7, 230	31
1387	A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis. 2017 , 2017, 1093858	12
1386	Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. 2017 , 2017, 1278268	26
1385	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. 2017 , 2017, 4719194	53
1384	CD80 Expressed by CD8 T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 T Cells. 2017 , 2017, 7659462	21
1383	Asymptomatic Pancreatic Metastasis from Renal Cell Carcinoma Diagnosed 21 Years after Nephrectomy. 2017 , 2017, 8765264	6
1382	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. 2017 , 1, 179-187	1
1381	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8
1380	Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy. 2017 , 2017, 5063405	6

1379	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. 2017 , 57, 191-197	13
1378	The current status of immunobased therapies for metastatic renal-cell carcinoma. 2017 , 6, 83-93	8
1377	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. 2018 , 15, 3061-3067	8
1376	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. 2017 , 8, 1460-1465	9
1375	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. 2017 , 9, 553-563	11
1374	Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. 2017 , 13, 799-806	16
1373	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor. 2017 , 9, 6867	7
1372	Expression of minichromosome maintenance genes in renal cell carcinoma. 2017 , 9, 637-647	24
1371	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. 2017 , 9, 207-213	90
1370	Current Management Options in Metastatic Renal Cell Cancer. 2017 , 11, 339	10
1369	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. 2017 , 10, 1487-1502	8
1368	Targeted therapy for soft tissue sarcomas in adolescents and young adults. 2017 , 8, 41-55	8
1367	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. 2017 , 13,	
1366	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. 2017 , 12, e0183639	2
1365	Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. 2017 , 12, e0184423	31
1364	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. 2017 , 6, e1344805	97
1363	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
1362	Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. 2017 , 17, 74	7

1361	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. 2017 , 16, 149	165
1360	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. 2017 , 12, 157	18
1359	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. 2017 , 10, 146	57
1358	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. 2017 , 10, 174	68
1357	Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications. 2017 , 9, 89	23
1356	Lingual metastasis as an initial presentation of renal cell carcinoma: a case report. 2017 , 11, 314	4
1355	Successful management of retinal metastasis from renal cancer with everolimus in a monophthalmic patient: a case report. 2017 , 11, 340	8
1354	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. 2017 , 5, 53	432
1353	Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition. 2017 , 5, 62	15
1352	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 2017 , 5, 66	27
1351	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. 2017 , 5, 82	53
1350	Biomarkers for immunotherapy in bladder cancer: a moving target. 2017 , 5, 94	100
1349	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. 2017 , 3, 94	12
1348	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. 2017 , 17, 880	8
1347	The 150 most important questions in cancer research and clinical oncology series: questions 57-66 : Edited by Chinese Journal of Cancer. 2017 , 36, 79	1
1346	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. 2017 , 5, 84	4
1345	Rho GDP dissociation inhibitor- β in renal cell carcinoma. 2017 , 14, 8190-8196	4
1344	Nivolumab Therapy for Synchronous -Positive Lung Cancer and Gastric Cancer. 2017 , 10, 361-367	3

1343	PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed. 2017 , 8, 66293-66304	8
1342	Severe Esophagitis and Gastritis from Nivolumab Therapy. 2017 , 4, e57	49
1341	Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. 2017 , 8, 61618-61625	8
1340	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. 2017 , 8, 67094-67103	25
1339	Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. 2017 , 1, 57-64	6
1338	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. 2017 , 1, 123-132	23
1337	Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. 2017 , 1, 31-40	6
1336	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. 2017 , 1, 15-29	4
1335	A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma. 2017 , 1, 83-88	1
1334	Cancer Immunotherapy. 2017 , 32-65	1
1333	Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. 2017 , 1, 133-141	8
1332	Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. 2017 , 1, 115-121	5
1331	Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. 2017 , 11, E237-E239	4
1330	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. 2017 , 10, 4885-4893	4
1329	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. 2017 , 11, 1175-1182	10
1328	Tumor location impacts immune response in mouse models of colon cancer. 2017 , 8, 54775-54787	44
1327	Advances on immunotherapy in genitourinary and renal cell carcinoma. 2017 , 6, 17-29	8
1326	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. 2017 , 11, 310-320	6

1325	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. 2017 , 8, 8910-8920	93
1324	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. 2017 , 11, 2801-2811	39
1323	Clinical Significance and Therapeutic Potential of the Programmed Death Ligand-1 (PD-L1) and PD-L2 Expression in Human Colorectal Cancer. 2017 , 09,	2
1322	Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?. 2017 , 10, 1335-1344	1
1321	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. 2017 , 7,	12
1320	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. 2017 , 1, 447-456	2
1319	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. 2017 , 8, 41641-41669	13
1318	Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma. 2017 , 1, 49-56	26
1317	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. 2017 , 8, 37-53	40
1316	Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. 2017 , 8, 3355-3363	13
1315	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. 2017 , 8, 8890-8899	37
1314	Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. 2017 , 2,	173
1313	Too Much or Just Enough of a Good Thing: Vascular Endothelial Growth Factor Inhibition in Renal Cell Carcinoma?. 2017 , 35, 1755-1757	
1312	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. 2017 , 35, 3851-3858	272
1311	Hypermutation and microsatellite instability in gastrointestinal cancers. 2017 , 8, 112103-112115	46
1310	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 2017 , 35, 3924-3933	495
1309	Triple-Negative Breast Cancer: Current Practice and Future Directions. 2017 , 13, 301-303	43
1308	Can Prostate Cancer Really Respond to Immunotherapy?. 2017 , 35, 4-5	6

1307	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. 2017 , 8, 12417-12432	19
1306	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. 2017 , 2017,	28
1305	Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 2017 , 37, 337-342	15
1304	Hodgkin lymphoma and PD-1 blockade: an unfinished story. 2017 , 1, 1-1	4
1303	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. 2017 , 8, 106132-106142	109
1302	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. 2017 , 8, 41-54	5
1301	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. 2017 , 1, 132-142	2
1300	The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. 2017 , 6, 131-133	10
1299	Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. 2017 , 8, 33614-33620	33
1298	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. 2017 , 8, 3197-3205	29
1297	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. 2018 , 196, 62-70	3
1296	Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. 2018 , 16, e735-e742	10
1295	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. 2018 , 7, e1440168	25
1294	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. 2018 , 4, 522-528	56
1293	The Role of Circulating Tumor DNA in Renal Cell Carcinoma. 2018 , 19, 10	23
1292	Targeting the microenvironment in solid tumors. 2018 , 65, 22-32	189
1291	A randomized phase II trial of interleukin-2 and interferon- β plus bevacizumab versus interleukin-2 and interferon- β in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. 2018 , 57, 589-594	13
1290	Nivolumab in the treatment of advanced renal cell carcinoma. 2018 , 14, 1679-1689	2

1289	Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. 2018 , 16, e711-e718	0
1288	Targeting the PI3K pathway in cancer: are we making headway?. 2018 , 15, 273-291	491
1287	Immune Checkpoint Inhibition in Hodgkin Lymphoma. 2018 , 2, e20	8
1286	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. 2018 , 6, 250-254	3
1285	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. 2018 , 4, eaar2766	254
1284	Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. 2018 , 18, 449-457	17
1283	Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. 2018 , 45, 408-415	27
1282	FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. 2018 , 81, 739-744	11
1281	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. 2018 , 29, 1320-1324	21
1280	Systemic immune-inflammation index in germ-cell tumours. 2018 , 118, 831-838	52
1279	The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. 2018 , 7, e1414119	30
1278	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. 2018 , 23, 410-420	40
1277	Cancer immunotherapy in patients with brain metastases. 2018 , 67, 703-711	11
1276	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. 2018 , 19, 16	5
1275	Drug discovery targeting the mTOR pathway. 2018 , 132, 543-568	46
1274	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. 2018 , 67, 805-814	27
1273	Durvalumab in urothelial cancers. 2018 , 18, 311-318	6
1272	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review. 2018 , 23, 540-555	42

1271	Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers. 2018 , 14, 337-342	2
1270	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. 2018 , 24, 2559-2573	95
1269	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. 2018 , 25, 1814-1827	30
1268	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. 2018 , 115, 119-124	12
1267	High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma. 2018 , 109, 1583-1591	42
1266	Renal cell carcinoma for the nephrologist. 2018 , 94, 471-483	38
1265	Drug review: Pazopanib. 2018 , 48, 503-513	31
1264	Target Therapy for Esophageal Adenocarcinoma. 2018 , 1756, 51-65	2
1263	Role of metastasis-directed treatment in kidney cancer. 2018 , 124, 3641-3655	29
1262	Representation of obese participants in obesity-related cancer randomized trials. 2018 , 29, 1582-1587	9
1261	Towards predictive biomarkers for immunotherapy response in breast cancer patients. 2018 , 7, BMT05	4
1260	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. 2018 , 7, e1457602	6
1259	Immunotherapie in de oncologie. 2018 , 34, 108-116	
1258	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. 2018 , 34, 970-971	
1257	Tumour cell expression of interleukin 6 receptor is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. 2018 , 4, 114-123	8
1256	[Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors : Immune-mediated side effects]. 2018 , 57, 543-551	3
1255	Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. 2018 , 81, 1061-1070	24
1254	Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. 2018 , 10, 109-123	22

1253	Investigation of the relationship of Epstein-Barr virus with in situ hybridization in renal-cell carcinomas. 2018 , 34, 45-49	2
1252	Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. 2018 , 143, 1162-1175	33
1251	Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. 2018 , 20, 41	13
1250	Regulatory T cells: a potential target in cancer immunotherapy. 2018 , 1417, 104-115	123
1249	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. 2018 , 23, 313-326.e5	295
1248	Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. 2018 , 36, 726-731	11
1247	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. 2018 , 124, 2897-2905	4
1246	T Cell Dysfunction in Cancer. 2018 , 33, 547-562	446
1245	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. 2018 , 95, 68-74	13
1244	Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma. 2018 , 4,	10
1243	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. 2018 , 11, 475-486	52
1242	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. 2018 , 20, 44	33
1241	Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort. 2018 , 36, 1423-1429	4
1240	Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma. 2018 , 50, 1-10	9
1239	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. 2018 , 105, 263-274	10
1238	Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. 2018 , 109, 24-28	79
1237	Present status and future perspective of peptide-based vaccine therapy for urological cancer. 2018 , 109, 550-559	28
1236	Renal Cell Carcinoma. 2018 , 225-236	

1235	A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer. 2018 , 18, 255-265	7
1234	[Immunotherapy in renal cell carcinoma: A booming clinical research]. 2018 , 28, 137-145	1
1233	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. 2018 , 7, e1433982	23
1232	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. 2018 , 16, 176-183	10
1231	Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. 2018 , 31, 965-973	138
1230	Metastatic Renal Cell Cancer-Systemic Therapy. 2018 , 9, 97-104	0
1229	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. 2018 , 118, 679-697	8
1228	Temozolomide-associated hypermutation in gliomas. 2018 , 20, 1300-1309	69
1227	Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. 2018 , 81, 679-686	8
1226	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 2018 , 13, 1-20	23
1225	IL-2 and Beyond in Cancer Immunotherapy. 2018 , 38, 45-68	41
1224	Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. 2018 , 19, 6	30
1223	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. 2018 , 7, e1431088	45
1222	IDO1 in cancer: a Gemini of immune checkpoints. 2018 , 15, 447-457	148
1221	Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. 2018 , 10, 171-175	11
1220	T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. 2018 , 87, e12643	16
1219	Radiation effects on antitumor immune responses: current perspectives and challenges. 2018 , 10, 17588340177492575	148
1218	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. 2018 , 10, 1758834017749748	128

1217	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. 2018 , 10, 1758834017751634	23
1216	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. 2018 , 3, e000278	136
1215	Role of immune-checkpoint inhibitors in lung cancer. 2018 , 12, 1753465817750075	58
1214	Kidney cancer in 2017: Challenging and refining treatment paradigms. 2018 , 15, 77-78	1
1213	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β 2018 , 10,	239
1212	Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. 2018 , 1711, 333-349	7
1211	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). 2018 , 143, 45-51	52
1210	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. 2018 , 24, 4175-4186	223
1209	Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma. 2018 , 40, 251-252	1
1208	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. 2018 , 19, 405-415	236
1207	Combination therapies for patients with metastatic renal cell carcinoma. 2018 , 19, 281-283	4
1206	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. 2018 , 8, 2592	57
1205	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. 2018 , 6, 402-408	42
1204	Translation in Immunology. 2018 , 1-11	
1203	Somatic Mutations and Immunotherapy. 2018 , 24-36	1
1202	Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. 2018 , 19, 2	5
1201	Hypermutated Tumors and Immune Checkpoint Inhibition. 2018 , 78, 155-162	16
1200	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. 2018 , 3, e000257	40

1199	Collection of real-world data on nivolumab's effectiveness in renal cell carcinoma: rationale for an observational study. 2018 , 14, 1023-1034	1
1198	Checkpoint Inhibitors, Palliative Care, or Hospice. 2018 , 20, 2	8
1197	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. 2018 , 24, 1805-1815	38
1196	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. 2018 , 24, 1296-1304	99
1195	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. 2018 , 7, e1413519	15
1194	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. 2018 , 18, 165-175	33
1193	Nivolumab for the treatment of urothelial cancers. 2018 , 18, 215-221	14
1192	Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond. 2018 , 24, 20-30	14
1191	Refractory thyroid carcinoma: which systemic treatment to use?. 2018 , 10, 1758834017752853	13
1190	Individualized dosing with axitinib: rationale and practical guidance. 2018 , 14, 861-875	6
1189	Reintroducing Pazopanib Reverses the Primary Resistance of Nivolumab in a Patient With Metastatic Clear-cell Renal Cell Carcinoma. 2018 , 16, 114-116	4
1188	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. 2018 , 10, 85-91	25
1187	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. 2018 , 10, 139-148	10
1186	Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2018 , 13, 97-105	121
1185	Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. 2018 , 16, e577-e586	11
1184	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. 2018 , 9, 5-11	51
1183	Merkel cell carcinoma: An update and review: Current and future therapy. 2018 , 78, 445-454	62
1182	Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis. 2018 , 56, 195-198	5

1181	Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma. 2018 , 121, 45-50	9
1180	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. 2018 , 4, 326-332	36
1179	Therapeutic Cancer Vaccines: How Much Closer Are We?. 2018 , 32, 1-7	11
1178	Pembrolizumab for the treatment of bladder cancer. 2018 , 18, 107-114	9
1177	Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. 2018 , 81, 347-354	3
1176	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. 2018 , 23, 410-421	15
1175	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. 2018 , 391, 748-757	753
1174	PD-1 Blockade in Renal Cell Carcinoma. 2018 , 345-355	
1173	Immunotherapy for Prostate Cancer: An Evolving Landscape. 2018 , 593-606	2
1172	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. 2018 , 36, 417-425	16
1171	Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review. 2018 , 9, 265-274	4
1170	Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. 2018 , 23, 155-e17	14
1169	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. 2018 , 52, 241-252	9
1168	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. 2018 , 124, 925-933	21
1167	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. 2018 , 24, 2268-2275	53
1166	Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. 2018 , 91, 11-20	36
1165	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. 2018 , 23, 559-567	10
1164	Improving immune-vascular crosstalk for cancer immunotherapy. 2018 , 18, 195-203	170

1163	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. 2018 , 27, 163-170	4
1162	Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells. 2018 , 78, 353-364	29
1161	Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?. 2018 , 29, 324-331	13
1160	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. 2018 , 16, e563-e575	52
1159	Sarcomatoid renal cell carcinoma: Biology and treatment advances. 2018 , 36, 265-271	26
1158	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. 2018 , 24, 144-153	374
1157	Inhibitors of the PD-1 Pathway in Tumor Therapy. 2018 , 200, 375-383	82
1156	Molecular Biomarkers in the Clinical Management of Prostate Cancer. 2018 , 8,	10
1155	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. 2018 , 50, 96-103	18
1154	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. 2018 , 110, 777-786	36
1153	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. 2018 , 30, 13-22	53
1152	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. 2018 , 20, 674-686	233
1151	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. 2018 , 10,	206
1150	First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy. 2018 , 34, 825-831	9
1149	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. 2018 , 359, 801-806	562
1148	Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF β in Advanced Solid Tumors. 2018 , 24, 1287-1295	195
1147	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. 2018 , 6, 222-235	39
1146	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. 2018 , 360, k793	262

1145	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. <i>Lancet Oncol</i> 2018;19:405-15. 2018 , 74, e50	0
1144	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. 2018 , 6, 26	89
1143	Check point inhibitors a new era in renal cell carcinoma treatment. 2018 , 35, 85	25
1142	Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism. 2018 , 17, 1781-1792	16
1141	Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. 2018 , 18, 88	25
1140	Temozolomide for immunomodulation in the treatment of glioblastoma. 2018 , 20, 1566-1572	85
1139	Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. 2018 , 41, 286-290	4
1138	Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. 2018 , 41, 272-280	23
1137	Landmark Trials in Renal Cancer. 2018 , 2, 11-21	
1136	Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. 2018 , 360, j5748	39
1135	Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma. 2018 , 14, 1835-1845	2
1134	Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. 2018 , 67, 29-33	3
1133	Pembrolizumab-induced auto-immune type-1 diabetes in a patient with metastatic melanoma. 2018 , 48, 262-264	2
1132	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. 2018 , 118, 1296-1301	29
1131	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. 2018 , 38, 1063-1078	164
1130	Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma. 2018 , 25, 630-632	22
1129	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. 2018 , 13, 1204-1212	33
1128	Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. 2018 , 81, 116-118	13

1127	Immunotherapy and Prevention of Pancreatic Cancer. 2018 , 4, 418-428	146
1126	Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. 2018 , 71, 665-671	81
1125	Real-world evidence in metastatic renal cell carcinoma. 2018 , 104, 76-82	8
1124	Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL. 2018 , 4, FSO299	2
1123	Adjuvant therapy for advanced renal cell carcinoma. 2018 , 18, 663-671	11
1122	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. 2018 , 1461-1505	
1121	Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges. 2018 , 11, 117956111876575	
1120	Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. 2018 , 29, 1437-1444	376
1119	Liquid Biopsies and Cancer Immunotherapy. 2018 , 24, 78-83	12
1118	The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1. 2018 , 7, e1434468	34
1117	F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. 2018 , 46, 260-264	22
1116	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. 2018 , 34, 1059-1068	62
1115	WITHDRAWN: Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. 2018 ,	
1114	Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma. 2018 , 16, e557-e562	10
1113	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. 2018 , 94, 259-273	8
1112	Pseudoprogression and hyperprogression after checkpoint blockade. 2018 , 58, 125-135	89
1111	[The role of biomarkers in the diagnosis, prognosis and therapy of patients with immuno-oncological treatments of genito-urinary carcinomas]. 2018 , 49, 171-177	
1110	[Immunotherapy for renal cell carcinoma - current status]. 2018 , 49, 187-191	3

1109	[Current guideline-oriented follow-up of small renal masses : Applied risk scores and future outlook]. 2018 , 57, 300-306		1
1108	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. 2018 , 4, 1-7		5
1107	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. 2018 , 94, 87-94		25
1106	Regulation and Function of the PD-L1 Checkpoint. 2018 , 48, 434-452		783
1105	Recent advances in medical therapy for metastatic urothelial cancer. 2018 , 23, 599-607		15
1104	Immunotherapy in Advanced Renal Cancer - Is Cure Possible?. <i>New England Journal of Medicine</i> , 2018 , 378, 1344-1345	59.2	9
1103	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1277-1290	59.2	2064
1102	Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. 2018 , 14, 461-467		7
1101	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. 2018 , 9, 451-458		11
1100	Cancer immunotherapy using checkpoint blockade. 2018 , 359, 1350-1355		2480
1099	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. 2018 , 94, 179-186		53
1098	Prognostic and Predictive Factors for Renal Cell Carcinoma. 2018 , 13, 309-331		2
1097	Chemokines and cancer: new immune checkpoints for cancer therapy. 2018 , 51, 140-145		73
1096	[Systemic immune checkpoint inhibition : A promising treatment for urological tumors?]. 2018 , 57, 583-590		1
1095	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. 2018 , 2, 241-251		93
1094	Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma. 2018 , 16, e795-e805		6
1093	The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. 2018 , 7, e1448329		50
1092	Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. 2018 , 199, 43-52		23

1091	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. 2018 , 103, 318-331	16
1090	Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study. 2018 , 26, 489-494	31
1089	Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations. 2018 , 41, 568-575	15
1088	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. 2018 , 8,	8
1087	Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions. 2018 , 36, 17-22	10
1086	Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy. 2018 , 181, 76-84	25
1085	Toxicity profiles of immunotherapy. 2018 , 181, 91-100	40
1084	Clinical decision-making for immunotherapy in metastatic renal cell carcinoma. 2018 , 28, 29-34	6
1083	Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies. 2018 , 36, 23-30	16
1082	Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. 2018 , 29, 209-214	98
1081	The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. 2018 , 15, 251-259	15
1080	Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma. 2018 , 28, 35-41	6
1079	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. 2018 , 359, 91-97	2203
1078	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. 2018 , 4, 442-454	6
1077	Drug-Induced Lung Injury. 2018 ,	0
1076	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. 2018 , 29, 71-83	154
1075	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. 2018 , 24, 592-599	47
1074	T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy. 2018 , 7, e1382793	13

1073	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. 2018 , 4, 173-182	467
1072	Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules. 2018 , 67, 113-125	16
1071	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. 2017 ,	5
1070	Safety of shortened infusion times for combined ipilimumab and nivolumab. 2018 , 67, 135-140	2
1069	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. 2018 , 7, e1387706	56
1068	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. 2018 , 52, 216-227	11
1067	Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. 2018 , 142, 822-832	42
1066	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60	9
1065	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. 2017 ,	1
1064	Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice. 2018 , 16, e297-e305	5
1063	Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia. 2018 , 32, e72-e74	3
1062	PD-L1 inhibitors in the pipeline: Promise and progress. 2017 , 7, e1365209	27
1061	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. 2018 , 23, 71-83	34
1060	HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. 2018 , 67, 79-87	5
1059	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. 2018 , 24, 701-716	13
1058	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. 2017 ,	11
1057	Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 : Second-line Treatment in Metastatic Renal Cell Carcinoma. Can Immunotherapy Be Considered a Cost-effective Treatment?. 2018 , 73, e74	
1056	Role of Immunotherapy in Head and Neck Cancer. 2018 , 28, 12-16	47

1055	Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. 2018 , 26, 6-12	19
1054	Nivolumab in recurrent/metastatic head and neck cancers. 2018 , 14, 603-609	3
1053	Molecular Diagnosis and Targeted Therapy for Gastric Cancer. 2018 , 63-80	
1052	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. 2018 , 6, 139-150	119
1051	Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 ,	0
1050	Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. 2018 , 168, 337-348	3
1049	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. 2018 , 73, 311-315	104
1048	Mechanisms of Tumor Cell Intrinsic Immune Evasion. 2018 , 2, 213-228	38
1047	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 2018 , 89, 56-63	46
1046	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. 2018 , 27, 55-70	3
1045	Promising immunotherapy for prostate cancer. 2018 , 18, 109-120	3
1044	Current and future immunotherapies for thyroid cancer. 2018 , 18, 149-159	37
1043	Implications of the tumor immune microenvironment for staging and therapeutics. 2018 , 31, 214-234	182
1042	Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma. 2018 , 7, 75-86	13
1041	Expression of programmed death-1 in sentinel lymph nodes of breast cancer. 2018 , 117, 1131-1136	2
1040	Innate and acquired immune surveillance in the postdissemination phase of metastasis. 2018 , 285, 654-664	32
1039	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. 2018 , 15, 112-124	52
1038	Some statistical considerations in the clinical development of cancer immunotherapies. 2018 , 17, 49-60	17

1037	Immunotherapeutic Biomarkers and Selection Strategies. 2018 , 69-114	
1036	Why overall survival and not progression free survival improves in era of program death inhibitors. 2018 , 24, 398-399	0
1035	The inflammatory microenvironment and microbiome in prostate cancer development. 2018 , 15, 11-24	179
1034	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. 2018 , 7, e1396403	34
1033	Immune Checkpoint Combinations with Inflammatory Pathway Modulators. 2018 , 219-241	
1032	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. 2018 , 1869, 78-84	82
1031	Early Phase Cancer Immunotherapy. 2018 ,	1
1030	Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. 2018 , 14, 237-246	129
1029	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. 2018 , 200, 347-354	122
1028	Immune checkpoint inhibitors: new strategies to checkmate cancer. 2018 , 191, 133-148	48
1027	Hepatocellular carcinoma in the era of immunotherapy. 2018 , 42, 40-48	71
1026	Reply to Nelson Martinez Merizalde Balarezo, Mark Monroe Rivera, and Romina A. Tejada's Letter to the Editor re: Maud Rijnders, Ronald de Wit, Joost L. Boormans, Martijn P.J. Lolkema, Astrid A.M. van der Veldt. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. Eur Urol. 2017 , 73, e17-e18	
1025	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. 2018 , 67, 403-412	39
1024	SEOM clinical guideline for treatment of kidney cancer (2017). 2018 , 20, 47-56	10
1023	Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. 2018 , 69, 209-221	4
1022	Immunotherapy for kidney cancer: status quo and the future. 2018 , 28, 8-14	20
1021	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. 2018 , 24, 1260-1270	164
1020	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. 2018 , 193, 1-10	7

1019	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. 2018 , 58, 7-24	15
1018	Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. 2018 , 73, 628-634	44
1017	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. 2018 , 106, 89-100	11
1016	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 β Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. 2018 , 36, 867-874	198
1015	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. 2018 , 36, 757-764	33
1014	Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. 2018 , 4, 1-8	7
1013	Checkpoint inhibitor-associated autoimmunity. 2018 , 32, 781-802	9
1012	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. 2018 , 14, 72-76	5
1011	Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment. 2018 , 2, 95-102	
1010	Langfristige Vollremission mit Ipilimumab bei metastasiertem kastrationsresistentem Prostatakrebs: Fallbericht von zwei Patienten. 2018 , 5, 180-185	
1009	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. 2018 , 4, 1-6	15
1008	Immuntherapie beim metastasierten Nierenzellkarzinom effektiv. 2018 , 21, 23-24	
1007	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. 2018 , 36, 1588-1593	29
1006	Prognostication in Kidney Cancer: Recent Advances and Future Directions. 2018 , JCO2018790147	29
1005	Imaging Advances in the Management of Kidney Cancer. 2018 , JCO2018791236	7
1004	Personalized Management of Advanced Kidney Cancer. 2018 , 38, 330-341	17
1003	Keeping Expectations in Check With Immune Checkpoint Inhibitors. 2018 , 36, 1654-1657	32
1002	Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?. 2018 , JCO2018789131	2

1001	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. 2018 , JCO2018792259	28
1000	Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. 2018 , JCO2018792549	52
999	The Immunobiology of Kidney Cancer. 2018 , JCO2018792648	36
998	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). 2018 , 36, 3223-3230	176
997	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. 2018 , JCO2018790253	45
996	Patterns of Response and Progression to Immunotherapy. 2018 , 38, 169-178	128
995	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. 2018 , JCO1800632	33
994	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. 2018 , JCO1801198	
993	Kidney Cancer: Toxicity Management, Symptom Control, and Palliative Care. 2018 , JCO2018790188	2
992	Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population. 2018 , 4, 1-10	1
991	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. 2018 , 36, 342-349	70
990	Medikamentöse Therapie des Nierenzellkarzinoms. 2018 , 21, 84-93	
989	Gut microbiome: a key player in cancer immunotherapy. 2018 , 7, 479-480	7
988	Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. 2018 , 9, 143-159	32
987	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. 2018 , 10, S995-S998	1
986	Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. 2018 , 7, 703-715	91
985	Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. 2019 , 10, 48-60	10
984	Rare Case of Intracardiac Renal Cell Carcinoma Metastasis with Response to Nivolumab: Case Report and Literature Review. 2018 , 11, 861-870	6

983	Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. 2019 , 10, 161-165	9
982	Quick steps toward precision medicine in renal cell carcinoma. 2018 , 3, 283-285	
981	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. 2018 , 7, S198-S201	3
980	Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. 2018 , 11, 756-762	3
979	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. 2018 , 97, e12344	4
978	The growing role of precision and personalized medicine for cancer treatment. 2018 , 6, 79-100	103
977	The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma. 2018 , 2018, 1953571	9
976	Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study. 2019 , 10, 125-131	3
975	Role of immunotherapy in kidney cancer. 2018 , 12, 325-333	6
974	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. 2018 , 24, 183-193	
973	Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report. 2019 , 10, 244-248	12
972	Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report. 2018 , 97, e13173	10
971	Cancer du rein m̄tastatique : recommandations et perspectives en 1re ligne. 2018 , 105 Suppl 3, S235-S241	1
970	Immunoth̄rapie des glioblastomes. 2018 , 105 Suppl 1, S59-S67	1
969	Biomarqueurs pr̄dictifs de r̄ponse aux inhibiteurs de points de contr̄le immuns. 2018 , 105 Suppl 1, S80-S91	0
968	Traitement focal et traitement syst̄mique dans la prise en charge du cancer du rein m̄tastatique : une question de compl̄mentarit̄. 2018 , 105 Suppl 3, S221-S228	
967	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. 2018 , 9, 7942-7948	18
966	Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor. 2018 , 14, 511-513	3

965	Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy. 2018 , 41, 340-342	3
964	[French ccAFU guidelines' Update 2018-2020: Management of kidney cancer]. 2018 , 28 Suppl 1, R5-R33	1
963	. 2018 , 105 Suppl 3, S268-S279	
962	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. 2018 , 9, 15001-15014	22
961	The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria. 2018 , 9, 27752-27759	13
960	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. 2018 , 2018, 228424031879073	
959	. 2018 , 105 Suppl 3, S261-S267	
958	[Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs]. 2018 , 105, 1202-1208	1
957	Gastrointestinale Tumoren. Hoher medizinischer Bedarf für neue Therapieoptionen. 2018 , 41, 334-335	
956	Die Rolle von Biomarkern bei Diagnose, Prognose und Therapie von Patienten unter immunonkologischer Therapie mit urologischen Malignomen. 2018 , 39, 671-677	
955	Immunothérapie des cancers du rein. 2018 , 105 Suppl 1, S24-S34	
954	Cancer du rein métastatique : quels critères de choix en 2e ligne ? 2018 , 105 Suppl 3, S242-S254	
953	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. 2018 , 363, k4226	191
952	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. 2018 , 105, 88-102	37
951	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. 2018 , 9, 2431	61
950	Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma. 2018 , 4,	10
949	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. 2018 , 10, 1303-1313	1
948	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. 2018 , 11, 7529-7542	20

947	Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies. 2018 , 11, 8239-8250	23
946	Predictors of immunotherapy-induced immune-related adverse events. 2018 , 25, e403-e410	46
945	Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. 2018 , 25, e444-e453	6
944	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. 2018 , 17, 1197-1209	8
943	Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. 2018 , 28, 479-484	4
942	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. 2018 , 6, 128	138
941	mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans. 2018 , 10,	7
940	Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. 2018 , 18, 1114	12
939	Management of immunotherapy toxicities in older adults. 2018 , 45, 226-231	12
938	Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. 2018 , 10, 1315-1323	3
937	The Identification of Immunological Biomarkers in Kidney Cancers. 2018 , 8, 456	32
936	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. 2018 , 7, e1500108	34
935	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. 2018 , 6, 114	29
934	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61
933	The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies. 2018 , 19, 70	12
932	Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. 2018 , 5, 6-13	6
931	Expression of PTEN-long nephritis and its effect on renal inflammation. 2019 , 17, 1405-1411	3
930	Analysis of PD-1 related immune transcriptional profile in different cancer types. 2018 , 18, 218	12

929	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. 2018 , 6, 156	33
928	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. 2018 , 6, 159	29
927	The promise of immunotherapy in genitourinary malignancies. 2018 , 1, 97-101	2
926	Isolated adrenocorticotrophic hormone deficiency potentially induced by nivolumab following pseudo-progression in clear cell renal cell carcinoma: A case report. 2019 , 10, 304-308	7
925	Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma. 2018 , 97, e13810	9
924	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. 2018 , 13, e0208422	10
923	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. 2018 , 10, 205-217	7
922	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. 2018 , 10, 6457-6468	14
921	Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. 2018 , 18, 1271	2
920	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. 2019 , 8, e1801099	17
919	Organoid Modeling of the Tumor Immune Microenvironment. 2018 , 175, 1972-1988.e16	478
918	Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?. 2018 , 14, 2997-2999	6
917	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. 2018 , 7,	38
916	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. 2018 , 19,	17
915	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. 2018 , 9, 4325-4333	12
914	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. 2018 , 6, 130	8
913	Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. 2018 , 19, 77	3
912	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. 2018 , 103, 259-266	8

911	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. 2018 , 154, 1416-1423	111
910	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. 2018 , 78, 6413-6423	19
909	Activation of viral defense signaling in cancer. 2018 , 10, 1758835918793105	9
908	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. 2018 , 13, 611-619	2
907	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. 2018 , 6, 1511-1523	39
906	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. 2018 , 10, 1123-1132	8
905	Alternate Fractionation in Radiotherapy. 2018 ,	
904	Roles of the immune system in cancer: from tumor initiation to metastatic progression. 2018 , 32, 1267-1284	688
903	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. 2018 , 71, 1078-1083	19
902	Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. 2018 , 6, 101	20
901	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. 2018 , 15, 116-123	31
900	Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. 2018 , 6, 97	9
899	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. 2018 , 124, 3677-3683	38
898	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. 2018 , 36, 526.e13-526.e18	18
897	Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. 2018 , 8, 15658	27
896	RETRACTED: Recommandations françaises du Comité de Cancérologie de l'AFU l'Actualisation 2018-2020: prise en charge du cancer du rein French ccAFU guidelines l'Update 2018-2020: Management of kidney cancer. 2018 , 28, S3-S31	8
895	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. 2018 , 5,	11
894	Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. 2018 , 11, 1756284818808086	8

893	Next generation immune-checkpoints for cancer therapy. 2018 , 10, S1581-S1601	38
892	Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy. 2018 , 19,	15
891	Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. 2018 , 22, 17-149	7
890	[Mode of action, new targets and potential biomarkers in modern immunotherapy]. 2018 , 57, 1301-1308	1
889	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. 2018 , 13, 1906-1918	50
888	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. 2018 , 6, 109	105
887	Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. 2018 , 16, 6003-6012	5
886	[Risk-adapted (immuno)therapy for renal cell carcinoma]. 2018 , 57, 1326-1333	0
885	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
884	Aging, immune senescence, and immunotherapy: A comprehensive review. 2018 , 45, 187-200	40
883	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106	85
882	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 2018 , 13, 705-714	24
881	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 2018 , 29, 911-913	2
880	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. 2018 , 109, 3583-3590	68
879	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. 2018 , 119, 950-960	83
878	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. 2018 , 6, 103	89
877	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
876	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. 2018 , 119, 911-912	5

875	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. 2018 , 9, 2265	77
874	Contemporary treatment of metastatic renal cell carcinoma. 2018 , 35, 156	24
873	Interleukin-6 induces drug resistance in renal cell carcinoma. 2018 , 64, 103-110	24
872	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. 2018 , 6, 107	36
871	[Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]. 2018 , 57, 1316-1325	2
870	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. 2018 , 132, 125-129	14
869	[Combining radiotherapy with immunotherapy for urological malignancies]. 2018 , 57, 1309-1315	2
868	Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. 2018 , 29, 2208-2213	93
867	Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. 2018 , 7, e1474318	16
866	Kidney cancer: The next decade. 2018 , 215, 2477-2479	59
865	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. 2018 , 12, 262	32
864	Advances in oncological treatment: limitations of RECIST 1.1 criteria. 2018 , 62, 129-139	15
863	Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. 2018 , 12, 412-418	8
862	Immune checkpoint inhibitors for urothelial carcinoma. 2018 , 59, 285-296	55
861	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. 2018 , 78, 1443-1457	41
860	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. 2018 , 103, 7-16	32
859	Renal cancer: new models and approach for personalizing therapy. 2018 , 37, 217	9
858	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. 2018 , 14, 3187-3198	7

857	Treating patients with renal cell carcinoma and bone metastases. 2018 , 18, 1135-1143	8
856	Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. 2018 , 35, 226-231	7
855	Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. 2018 , 7, 212528	52
854	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. 2018 , 119, 663-669	48
853	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. 2018 , 362, k3529	205
852	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. 2018 , 74, 818-851	3
851	Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. 2018 , 24, 6383-6395	33
850	The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer. 2018 , 10, 1047-1052	6
849	Genitourinary Cancers. 2018 ,	
848	Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. 2018 , 38, 4987-4997	23
847	Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. 2018 , 38, 5387-5392	7
846	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. 2018 , 29, 2175-2182	13
845	Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview of technical aspects, biological rationale and current literature. 2018 , 131, 24-29	12
844	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. 2018 , 56, 118-125	9
843	Impact of PD-L1, transforming growth factor- β expression and tumor-infiltrating CD8 T cells on clinical outcome of patients with advanced thymic epithelial tumors. 2018 , 9, 1341-1353	10
842	Current Role of Checkpoint Inhibitors in Urologic Cancers. 2018 , 175, 241-258	5
841	Strategies for Predicting Response to Checkpoint Inhibitors. 2018 , 13, 383-395	17
840	Application of dynamic modeling for survival estimation in advanced renal cell carcinoma. 2018 , 13, e0203406	1

839	The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials. 2018 , 47-55	
838	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. 2018 , 49, 227-236	21
837	Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. 2018 , 164, 178-184	49
836	Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. 2018 , 20, 423-435	9
835	, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. 2018 , 24, 5710-5723	150
834	Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma. 2018 , 79, 102-108	10
833	An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. 2018 , 18, 695-705	2
832	What is the role of nephrectomy following complete response to checkpoint inhibitors?. 2018 , 18, 60-63	15
831	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
830	A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. 2018 , 9, 203-210	21
829	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. 2018 , 119, 160-163	25
828	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30
827	The Role of DNA Methylation in Renal Cell Carcinoma. 2018 , 22, 431-442	29
826	Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis. 2018 , 41, 1235-1242	3
825	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. 2018 , 14, 1347-1354	7
824	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. 2018 , 74, 611-620	49
823	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177	19
822	Development of an Enzyme-Linked Immune Sorbent Assay to Measure Nivolumab and Pembrolizumab Serum Concentrations. 2018 , 40, 596-601	10

821	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. 2018 , 19, e317-e326	23
820	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. 2018 , 24, 4399-4406	23
819	Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged . 2018 , 38, 3593-3599	3
818	Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy. 2018 , 3, 399-404	15
817	Management immunvermittelter Nebenwirkungen. 2018 , 34, 38-48	
816	Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. 2018 , 127, 501-506	34
815	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. 2018 , 19, 737-746	353
814	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. 2018 , 16, 341-348	4
813	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
812	Nivolumab for the treatment of colorectal cancer. 2018 , 18, 611-618	24
811	Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry. 2018 , 16, e1101-e1115	9
810	Comment l'urologue et son rseau de soin peuvent prendre en charge la toxicit'des immunothfapies? Application aux toxicit's pulmonaires. 2018 , 28, F40-F42	
809	Chemotherapy plus nivolumab-associated acute kidney injury in a patient with non-oropharyngeal head and neck squamous cell carcinoma with renal metastasis. 2018 , 5, 116-118	1
808	Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. 2018 , 122, 234-242	15
807	Targeting tumor-associated acidity in cancer immunotherapy. 2018 , 67, 1331-1348	38
806	Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies. 2018 , 17, 1355-1364	98
805	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. 2018 , 118, 1176-1178	28
804	Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. 2018 , 36, 973-986	9

803	Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. 2018 , 2018, 4273231	5
802	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. 2018 , 2018, 9602540	14
801	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. 2018 , 33, 94-104	6
800	Genetic and metabolic hallmarks of clear cell renal cell carcinoma. 2018 , 1870, 23-31	54
799	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. 2018 , 1, e180416	30
798	Drug Class Analysis. 2018 , 441-511	1
797	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". 2018 , 69, 121-131	27
796	Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients. 2018 , 22, 755-761	6
795	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. 2018 , 13, 1569-1576	140
794	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. 2018 , 24, 5534-5542	10
793	Minimal change disease associated with anti-PD1 immunotherapy: a case report. 2018 , 19, 156	16
792	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. 2018 , 6, 40	76
791	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 10,	24
790	Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. 2018 , 13, 447-459	6
789	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. 2018 , 24, 5977-5989	44
788	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. 2018 , 12, 1645-1657	13
787	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. 2018 , 19,	32
786	mTOR and Tumor Cachexia. 2018 , 19,	19

785	Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers. 2018 , 15, 4988-4996	10
784	Patient-reported outcomes with nivolumab in advanced solid cancers. 2018 , 70, 75-87	11
783	Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL. 2018 , 38, 4505-4514	7
782	Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies. 2018 , 129, 133-145	18
781	Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. 2018 , 6, 16	22
780	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. 2018 , 9, 2302-2307	16
779	The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. 2018 , 48, 835-840	6
778	Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?. 2020 , 12, e10525	0
777	Radiological Imaging of Adverse Events to Immunotherapy. 2020 , 3, 44-53	
776	[French ccAFU guidelines - update 2020-2022: management of kidney cancer]. 2020 , 30, S2-S51	3
775	Nicht-interventionelle Studie beim fortgeschrittenen Nierenzellkarzinom in der Erstlinientherapie. 2020 , 51, 528-529	
774	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. 2020 , 14, 199-204	
773	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. 2020 , 14, 205-212	
772	Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis. 2020 , 3, 172-174	3
771	Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. 2020 ,	
770	Immunotherapy induced enterocolitis and gastritis - What to do and when?. 2020 , 48-49, 101703	3
769	European Cancer Congress 2015. 2015 , 40, 769-71	
768	Management of high-risk localized kidney cancer: NYU Case of the Month, September 2017. 2017 , 19, 187-189	1

767	[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application]. 2017 , 20, 645-651	
766	Immunotherapy in Urological Tumors. 2019 , 21, 15-20	4
765	Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. 2019 , 9, 2442-2455	9
764	[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors]. 2019 , 22, 786-793	
763	The Role of Immunotherapy in Urologic Cancers. 2020 , 117, 127-132	0
762	Recombinant Expression and Purification of Extracellular Domain of the Programmed Cell Death Protein Receptor. 2020 , 8, 347-357	
761	[Advances on PD-1/PD-L1 inhibitors in multiple myeloma]. 2018 , 39, 261-264	
760	[Role of programmed death-1 in viral infectious diseases]. 2018 , 20, 77-82	1
759	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. 2020 , 12, 5416-5432	4
758	Down-regulation of UL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma. 2020 , 12, 6509-6523	1
757	GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma. 2020 , 10, 3705-3720	4
756	Oncogenic potential of macrophage-capping protein in clear cell renal cell carcinoma. 2021 , 23,	
755	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. 2020 , 12, 22509-22526	4
754	Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors. 2020 , 3, 17-21	1
753	Preclinical development and characterisation of Tc-NM-01 for SPECT/CT imaging of human PD-L1. 2021 , 11, 154-166	0
752	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. 2021 , 11, 683502	1
751	The Identification of a Tumor Infiltration CD8+ T-Cell Gene Signature That Can Potentially Improve the Prognosis and Prediction of Immunization Responses in Papillary Renal Cell Carcinoma. 2021 , 11, 757641	0
750	Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.. 2021 , 28, 5019-5024	

749	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. 2021 ,	2
748	Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. 2021 , 13,	3
747	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. 2021 , 13,	3
746	Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy. 2021 , 100805	0
745	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. 2021 , 9,	2
744	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. 2021 , 114033	0
743	The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. 2021 , 21, 1238	1
742	Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling.. 2021 , 11, 758989	1
741	Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. 2021 , 10,	5
740	Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. 2021 ,	2
739	Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. 2021 , 20, 78-84	
738	Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. 2021 , 21, 1222	3
737	Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients. 2021 , 19, 252-260	
736	Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. 2021 , 8, 763271	1
735	Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study. 2022 , 16, 17	1
734	B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. 2021 ,	1
733	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. 2021 , 13,	0
732	A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. 2021 , 1	2

731	LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma.. 2021 , 8, 711928	
730	Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study).. 2022 , 32, 69-75	1
729	Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. 2021 , 9,	1
728	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. 2021 , 13,	2
727	Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. 2021 , 13,	4
726	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. 2021 , 2021, 8970173	3
725	Dual inhibition of TGF- β and PD-L1: a novel approach to cancer treatment. 2021 ,	1
724	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. 2021 , 6, 100304	0
723	Rational combination with an immunotherapy backbone in genitourinary cancers. 2020 , 31, 4	0
722	Current and future aspect of immunotherapy for advanced renal cell carcinoma. 2020 , 31, 8	1
721	Renal Toxicity.. 2021 , 1342, 389-397	
720	Immune Checkpoint Blockade for Genitourinary Malignancies and the Abscopal Response. 2021 , 551-559	
719	Landscape of Immunotherapy in Genitourinary Malignancies.. 2021 , 1342, 143-192	0
718	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood.. 2021 , 35, 20587384211056505	1
717	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials.	
716	Outcomes of starting low-dose pazopanib in patients with metastatic renal cell carcinoma who do not meet eligibility criteria for clinical trials. 2021 , 32, 104	0
715	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.. 2021 ,	8
714	Biomarkers of Immunotherapy Response and the Future Role of Targeted Therapies in Non-metastatic Prostate Cancer. 2022 , 161-176	

713	The Future of Artificial Intelligence Applied to Perioperative Immunotherapy Trials: Renal Cell Carcinoma. 2022 , 299-302	
712	Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.. 2022 , 1	1
711	A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases.. 2022 , 15, 325-342	
710	OUP accepted manuscript.	0
709	Biomarkers for predicting the efficacy of immune checkpoint inhibitors.. 2022 , 13, 481-495	1
708	OUP accepted manuscript.	0
707	Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. 2021 ,	1
706	The renal clear cell carcinoma immune landscape.. 2022 , 24, 145-154	0
705	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.. 2021 , 146, 112516	7
704	The total flavonoids of Hippophae rhamnoides stimulate recruitment of CD8+ T cells into the tumor microenvironment promoting cancer immune control. 2022 , 2, 100204	
703	Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. 2020 , 46, 481-488	0
702	Neoadjuvant chemotherapy for upper tract urothelial carcinoma.. 2020 , 9, 6576-6582	0
701	Oncogenic potential of macrophage-capping protein in clear cell renal cell carcinoma. 2020 , 23,	0
700	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. 2020 , 12, 22509-22526	4
699	Novel emerging biomarkers to immunotherapy in kidney cancer. 2021 , 13, 17588359211059367	3
698	Systemtherapie beim metastasierten Nierenzellkarzinom. 2021 , 407-473	
697	Fortgeschrittenes Nierenzellkarzinom: Neuerungen beim Einsatz zielgerichteter Therapien.	
696	Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. 2021 , 11, 683502	2

695	Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma1. 2021 , 5, 181-187	
694	Immunotherapy. 2022 , 299-312	
693	Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?. 2022 ,	
692	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.. 2022 , 22, 99	2
691	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.. 2021 , 12, 779248	0
690	Integrative clinical and molecular characterization of translocation renal cell carcinoma.. 2022 , 38, 110190	3
689	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. 2022 , 14,	0
688	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.. 2022 , 21, 28	22
687	The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.. 2022 , 39, 41	0
686	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.. 2022 ,	2
685	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. 2022 , 20, 71-90	20
684	Exposure-Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma.. 2022 ,	0
683	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.. 2022 ,	2
682	Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.. 2022 , 23, 51	0
681	Experience of the nivolumab use in patients with metastatic renal cell carcinoma provided under the expanded access program in Russia. Subgroup analysis of the correlation between expression markers and the effectiveness of nivolumab therapy. 2022 , 11, 23-35	
680	A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma.. 2021 , 9, 812422	0
679	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma.. 2022 , 13, 28-38	2
678	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. 2022 , 7, 100899	0

677	Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature.. 2022 , 15, 475	1
676	CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.. 2021 , 432, 120089	0
675	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma.. 2022 ,	1
674	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. 2022 , 14,	0
673	Update on the treatment of metastatic renal cell carcinoma.. 2022 , 13, 1-8	1
672	Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?. 2022 , 39, 1107	1
671	A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy.. 2022 , 10, 102	0
670	Immune-checkpoint inhibitors: long-term implications of toxicity.. 2022 ,	34
669	Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data. 2022 , 12, 1563	1
668	Nivolumab induced hypophysitis in an advanced RCC patient.. 2022 , 10781552211072212	1
667	High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. 2021 ,	1
666	Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database.. 2022 , 12, 814512	1
665	Anti-Tumor Role of CAMK2B in Remodeling the Stromal Microenvironment and Inhibiting Proliferation in Papillary Renal Cell Carcinoma.. 2022 , 12, 740051	3
664	Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.. 2022 ,	1
663	Which test for crossing survival curves? A user's guideline.. 2022 , 22, 34	2
662	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.. 2021 , 103, 102333	4
661	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes.	2
660	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.. 2022 , 170, 103596	0

- 659 Global management of brain metastasis from renal cell carcinoma.. **2022**, 171, 103600
- 658 Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors.. **2022**, 1
- 657 Identification of Hypoxia-Immune-Related Gene Signatures and Construction of a Prognostic Model in Kidney Renal Clear Cell Carcinoma.. **2021**, 9, 796156 0
- 656 Emerging drug targets for colon cancer: A preclinical assessment.. **2022**, 1-10 1
- 655 Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.. **2022**, 1
- 654 Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer.. **2022**, 0
- 653 Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India.
- 652 A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis.. **2022**, 10781552221074315
- 651 Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study.. **2022**, 8258597221078391
- 650 Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers.. **2022**, 13, 810681 0
- 649 Recent insights into the use of immune checkpoint inhibitors in gastric cancer.. **2022**, 7, e162 1
- 648 Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. **2022**, 1-9
- 647 Renal Cell Carcinoma in Older Adults with Frailty. **2022**, 371-381
- 646 Nierenparenchymtumoren. **2022**, 1-23
- 645 Commensal Microbiota and Cancer Immunotherapy: Harnessing Commensal Bacteria for Cancer Therapy.. **2022**, 22, e3 1
- 644 A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.. **2022**, 38, e28 1
- 643 Overview of clinical management for older patients with renal cell carcinoma.. **2022**, 0
- 642 First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. **2022**, 82, 439 0

641	PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma.. 2022 , 14,	0
640	Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo.. 2022 , 27,	1
639	A web-based prediction model for overall survival of elderly patients with early renal cell carcinoma: a population-based study.. 2022 , 20, 90	0
638	The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration.. 2022 , 13, 833013	0
637	Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review.. 2022 , 14,	2
636	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.. 2022 , 17, 193	1
635	Recent pharmacological approaches for the treatment of renal cell carcinoma.. 2022 , 1-9	
634	Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective.. 2022 , 23, 268	1
633	REchallenge of NIVOLUMAB (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.. 2022 , 2022, 3449660	1
632	The New Era of Immunotherapy in Gastric Cancer.. 2022 , 14,	6
631	Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma.. 2022 , 15, 1099-1116	0
630	A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.. 2022 , 58,	1
629	Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. 2022 , 16, 10-15	
628	Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment.. 2022 , 14,	4
627	What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination.. 2022 , 11, 2038403	0
626	Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.. 2022 ,	1
625	Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report.. 2022 , 13, 799026	
624	A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment.. 2022 , 11, 134-137	1

623	Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma.. 2022,	0
622	Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing.. 2022, 23, 87	2
621	The MIF SNP rs755622 is a germline determinant of tumor immune activation in Glioblastoma.	
620	Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.. 2022, 2022, 5430525	
619	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.. 2022,	
618	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.. 2022, 13, 801909	
617	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.. 2022, 11, 11	3
616	Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.. 2022, 13, 803706	0
615	Le rôle des ganglions lymphatiques drainant la tumeur ^ rôle des immunothérapies. 2022,	
614	ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer.. 2022, 10, 808212	1
613	Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC).. 2022, 12, 832027	1
612	Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.. 2022, 10,	1
611	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours.. 2022, 164, 95-104	
610	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.. 2022,	2
609	A novel peptide-based probe ^{99m} Tc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. 2022,	1
608	CMTM6 as a master regulator of PD-L1.. 2022, 1	1
607	Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance.. 2022, 10, 818453	2
606	Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.. 2022,	2

605	Research progress on anti-tumor immune effect of cryoablation. 1	0
604	Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future.. 2022 , 14,	0
603	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.. 2022 , 10,	5
602	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.. 2022 , 25, 619	1
601	The Predictive Individual Effect for Survival Data.. 2022 , 56, 492-500	0
600	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.. 2022 , 10,	2
599	Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.. 2022 ,	0
598	Impressive response to Nivolumab in renal clear cell carcinoma skin metastasis.. 2022 ,	
597	Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma.. 2022 , 14, e23598	0
596	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.. 2022 ,	4
595	Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment.. 2022 , 15, 3043-3053	1
594	Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.. 2022 , 22, 297	
593	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-analysis of 22 randomized controlled trials.. 2022 ,	
592	Immunotherapy of glioblastoma: recent advances and future prospects.. 2022 , 1-16	0
591	Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis.. 2022 ,	0
590	[Immunotherapy in urologic oncology : Response and treatment interruptions due to adverse events in a bicentric real-world analysis].. 2022 , 1	
589	BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review. 2022 , 6, 23-35	0
588	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome.. 2022 , 23,	0

587	The clinical and prognostic significance of CMTM6/PD-L1 in oncology.. 2022 , 1	
586	PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.. 2022 ,	
585	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands.. 2022 , 13, 803935	0
584	Recent Advances in Medical Therapy for Urological Cancers.. 2022 , 12, 746922	2
583	Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.. 2022 ,	6
582	A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies.. 2022 , 13, 864423	0
581	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics.. 2022 , 12, 871252	0
580	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.. 2022 ,	8
579	Clinicians' perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors.	
578	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up.. 2022 ,	
577	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study.. 2022 ,	
576	Establishment of an Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma.. 2022 , 12, 851191	0
575	Predictive biomarkers for the efficacy of nivolumab as 3 rd -line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.. 2022 , 22, 378	0
574	Organoid Models for Precision Cancer Immunotherapy.. 2022 , 13, 770465	3
573	Balancing the good and the bad: controlling immune related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors.	1
572	Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma.. 2022 , 10, 874427	0
571	"The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scores.. 2022 , 7, 100413	
570	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.. 2022 , 20, 406-416.e11	3

569	Radiotherapy: Brightness and darkness in the era of immunotherapy.. 2022 , 19, 101366	5
568	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.. 2022 , 19, 101383	0
567	Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.. 2022 , 86, 31-37	
566	Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.. 2021 , 12, 794099	4
565	Phase Ib Study of Atezolizumab Plus Interferon- γ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.. 2021 , 28, 5466-5479	0
564	The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors.. 2021 ,	0
563	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. 2021 ,	1
562	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.. 2021 , 14, 109	2
561	Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.. 2021 , 12, 736860	0
560	Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of response to Immune Checkpoint Inhibitors in Gynecologic Cancers.. 2021 ,	1
559	Immunotherapy against Gliomas.	
558	Comprehensive analysis of pyroptosis regulators and tumor immune microenvironment in clear cell renal cell carcinoma.. 2021 , 21, 667	1
557	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.. 2021 ,	0
556	The foundations of immune checkpoint blockade and the ipilimumab approval decennial.. 2021 ,	15
555	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. 2021 , 17, 61	5
554	Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. 2021 , 11, e047663	
553	Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer.. 2021 , 13, 1567-1583	0
552	CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma.. 2021 , 9, 1741	0

551	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.. 2021 , 12, 775761	3
550	Case Report: Early Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases.. 2021 , 11, 782166	1
549	FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma.. 2021 , 11, 756843	2
548	Model-Based Characterization of the Bidirectional Interaction between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.. 2021 ,	
547	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.. 2022 , 13, 1935	3
546	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.. 2022 , 13, 835510	1
545	Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.. 2022 ,	0
544	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.. 2022 , 14, eabm6420	0
543	Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.. 2022 , 12, 851522	0
542	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.. 2022 , 13, 862084	0
541	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.. 2022 , 5, e227722	1
540	Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.. 2022 , 10,	1
539	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).. 2022 , JCO2102938	2
538	Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.. 2022 , 9, 793403	0
537	Use of immunotherapy in clinical management of genitourinary cancers - a review.. 2022 , 31, 100564	0
536	Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. 2022 , 10, 763	1
535	Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic.. 2022 , 12,	2
534	A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors.. 2022 , 108, 108775	0

533 DataSheet_1.pdf. **2021,**

532 Table_1.docx. **2021,**

531 Data_Sheet_1.docx. **2020,**

530 Table_1.xlsx. **2019,**

529 Table_2.xlsx. **2019,**

528 Table_3.xlsx. **2019,**

527 Table_4.xlsx. **2019,**

526 Table_5.xlsx. **2019,**

525 Table_6.xlsx. **2019,**

524 Table_7.xlsx. **2019,**

523 Table_1.XLSX. **2020,**

522 DataSheet_1.csv. **2020,**

521 Image_1.tif. **2020,**

520 Image_2.tif. **2020,**

519 Image_3.tif. **2020,**

518 Image_4.tif. **2020,**

517 Image_5.tif. **2020,**

516 Image_6.tif. **2020,**

515 Image_7.tif. 2020,

514 Image_8.tif. 2020,

513 Image_9.tif. 2020,

512 Table_1.docx. 2020,

511 Presentation_1.PPTX. 2019,

510 Presentation_1.PPTX. 2019,

509 Table_1.xlsx. 2019,

508 Table_2.xlsx. 2019,

507 Table_3.xlsx. 2019,

506 Table_4.docx. 2019,

505 Table_1.pdf. 2019,

504 Table_2.pdf. 2019,

503 Table_3.xlsx. 2019,

502 Table_4.xlsx. 2019,

501 Image_1.tif. 2020,

500 Image_2.tif. 2020,

499 Image_3.tif. 2020,

498 Image_4.tif. 2020,

497 Table_1.docx. **2020**,

496 Table_2.docx. **2020**,

495 Table_3.docx. **2020**,

494 Table_4.xlsx. **2020**,

493 Image_1.TIF. **2020**,

492 Table_1.xlsx. **2020**,

491 Table_2.xlsx. **2020**,

490 DataSheet_1.pdf. **2019**,

489 Image_1.jpeg. **2020**,

488 Image_2.jpeg. **2020**,

487 Image_3.jpeg. **2020**,

486 Image_4.jpeg. **2020**,

485 Data_Sheet_1.PDF. **2020**,

484 Data_Sheet_2.PDF. **2020**,

483 Data_Sheet_3.PDF. **2020**,

482 Data_Sheet_4.PDF. **2020**,

481 Data_Sheet_5.PDF. **2020**,

480 Image_1.pdf. **2020**,

479 Image_2.pdf. 2020,

478 Image_3.pdf. 2020,

477 Image_4.pdf. 2020,

476 Image_5.pdf. 2020,

475 Image_6.pdf. 2020,

474 Table_1.XLSX. 2020,

473 Table_10.XLSX. 2020,

472 Table_11.XLSX. 2020,

471 Table_12.XLSX. 2020,

470 Table_13.XLSX. 2020,

469 Table_14.XLSX. 2020,

468 Table_2.XLSX. 2020,

467 Table_3.XLSX. 2020,

466 Table_4.XLSX. 2020,

465 Table_5.XLSX. 2020,

464 Table_6.XLSX. 2020,

463 Table_7.XLSX. 2020,

462 Table_8.XLSX. 2020,

461 Table_9.XLSX. 2020,

460 Table_1.DOCX. 2020,

459 Table_1.DOCX. 2020,

458 Presentation_1.pdf. 2019,

457 Table_1.DOCX. 2020,

456 Table_2.DOCX. 2020,

455 Image_1.jpg. 2019,

454 Image_2.jpg. 2019,

453 Data_Sheet_1.docx. 2020,

452 Data_Sheet_1.docx. 2019,

451 Presentation_1.PPTX. 2019,

450 Data_Sheet_1.PDF. 2019,

449 DataSheet_1.pdf. 2019,

448 Data_Sheet_1.docx. 2019,

447 Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.. 2022, 2475, 1-23

446 Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.. 2022, 4

445 Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.. 2022,

444 Diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing time-dependent anti-tumor effects of the PD-1/PD-L1 inhibitor BMS-1 in B16/BL6 melanoma-bearing mice.. 2022, 1

- 443 The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.. **2021**, 11, 790381 ○
- 442 Dissecting the role of lymphadenectomy in the management of renal cell carcinoma: past, present, and future.. **2020**, 18, 103-108
- 441 Axitinib in management of renal cell carcinoma: Indian perspective. **2022**, 6, 14
- 440 Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.. **2022**, 183, 201-223
- 439 A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. **2022**, 1-13 1
- 438 Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer.. **2022**,
- 437 Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.. **2022**, ○
- 436 Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.. **2022**, 13, 869488 ○
- 435 Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis.. **2022**, 13, 11187-11207 ○
- 434 Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway.. **2022**, 13, 11240-11257 ○
- 433 Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond.. **2022**,
- 432 Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. **2022**, 15, 557 ○
- 431 What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.. **2022**, 14, ○
- 430 Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma.. **2022**, 13, 867627 4
- 429 A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. **2022**, 13, ○
- 428 Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. **2022**, 14, 2354 ○
- 427 Phase IB Study of G1TR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab or Nivolumab in Patients with Advanced Solid Tumors.. **2022**, 1
- 426 Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study.. **2022**, 14, 2

425	Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy.. 2022 ,	1
424	A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma.. 2022 ,	2
423	Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.. 2022 , 22, 497	0
422	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group.. 2022 , 1	1
421	Skin manifestations associated with checkpoint inhibitors.	0
420	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma.. 2022 ,	0
419	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.. 2022 , 13, 874589	1
418	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.. 2022 , 14,	0
417	Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma. 2022 , 2,	
416	Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.. 2022 , 13, 902060	1
415	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. 2022 , 17, e0268288	1
414	Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.. 2022 , 54, 1339-1349	0
413	The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials.. 2022 , 174, 103700	0
412	Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. 2022 , 40, 38-45	0
411	Considerations for personalized neoantigen vaccination in Malignant glioma.. 2022 , 186, 114312	1
410	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy.. 2022 , 42, 1-18	0
409	Kidney Cancer. 2022 , 233-245	
408	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis.. 2022 , 7, 100474	1

407	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).. 2022 , JCO2102660	10
406	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. 2022 , 14, 2460	
405	Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. 2022 , 13,	0
404	Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.. 2022 , 14,	
403	A novel four-gene signature predicts immunotherapy response of patients with different cancers.. 2022 , e24494	1
402	CD4 T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy.. 2022 , 10,	0
401	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.. 2022 , 42, 1-14	1
400	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. 2022 , 12, 1766-1783	
399	An analysis report on the application of immune checkpoint inhibitors after liver transplantation. 2022 , 13, 204062232210993	0
398	Genomic and transcriptomic landscape of advanced renal cell cancer to individualize treatment strategy.	
397	The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.	
396	A Visualized Dynamic Prediction Model for Overall Survival in Elderly Patients With Pancreatic Cancer for Smart Medical Services. 2022 , 10,	
395	Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab. 2022 , 8, 1363-1373	1
394	Safety and Efficacy of Second-Line TKI Plus Anti-PD1 Following Targeted Therapy in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study.	
393	CD21lo B Cells Could Be a Potential Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. 2022 , 12, 888	0
392	No Time to Die: How Kidney Cancer Evades Cell Death. 2022 , 23, 6198	0
391	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. 13,	1
390	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. 13,	1

389	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. 13,	1
388	Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: the CABIR study.	1
387	Therapeutic Potential of Natural Products in the Treatment of Renal Cell Carcinoma: A Review. 2022 , 14, 2274	0
386	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma.	1
385	Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.. 2022 ,	2
384	Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. 2022 , 10, e003960	0
383	Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.	0
382	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. 2022 ,	0
381	Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study. 2022 ,	0
380	Construction of a Prognostic Model for KIRC and Identification of Drugs Sensitive to Therapies - A Comprehensive Biological Analysis Based on m6A-Related LncRNAs. 12,	
379	Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. 2022 , 5,	0
378	Immuno-Oncologic Treatment of Genitourinary Malignancies. 2022 , 729-735	
377	Update on Treatment of Renal Cell Carcinoma. 2022 , 81, 77-81	
376	Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. 2022 , 109, 2S31-2S38	1
375	Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. 2022 , 22,	
374	Immune Checkpoint Inhibitor-Associated Myositis. Publish Ahead of Print,	0
373	Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. 2022 , 22,	
372	Tivozanib: A new hope of treating renal cell carcinoma. 2022 , 22,	

- 371 PD-1/PD-L Axis in Neuroinflammation: New Insights. 13, 0
- 370 Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. **2022**, 10, e004797 0
- 369 Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. **2022**, 9
- 368 An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. 0
- 367 Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR). 1
- 366 Resveratrol in cancer treatment with a focus on breast cancer. **2022**, 15, 0
- 365 Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. **2022**, 132, 0
- 364 Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience. 1
- 363 Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma. 0
- 362 Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. 13, 0
- 361 Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. 1-8 0
- 360 Cancer du rein m̄tastatique : gestion des toxicit̄s des combinaisons. **2022**, 0
- 359 Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies. **2022**, 4, 235-237 0
- 358 The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy. 0
- 357 Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. **2022**, 176, 103746 0
- 356 Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. **2022**, 110, 108900 3
- 355 Dual inhibition of TGF̄ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1. **2022**, 543, 215795 0
- 354 The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. **2022**, 14, 175883592211132 1

- 353 Mapping Single Cell Transcriptomes in the Intra-Tumoural and Associated Territories of Kidney Cancer.
- 352 Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. **2022**, 14, 175883592211086 ○
- 351 ICIs-Related Cardiotoxicity in Different Types of Cancer. **2022**, 9, 203 ○
- 350 Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma.
- 349 Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. ○
- 348 Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Publish Ahead of Print,
- 347 Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. **2022**, 14, 3214 ○
- 346 A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. 13, 1
- 345 RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. **2022**, 14, 3127 ○
- 344 Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. ○
- 343 Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. ○
- 342 A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. 2
- 341 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,
- 340 Cabozantinib in the treatment of patients with advanced renal cell carcinoma. **2022**, 24, 184-190
- 339 Efficacy and safety of concomitant proton pump inhibitor and nivolumab in renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. **2022**, ○
- 338 Single cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer. ○
- 337 Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression. 13,
- 336 Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. **2022**, 24, 191-198

- 335 Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. 2
- 334 Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice. **2022**, 12, 45-51
- 333 Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. **2022**, 1
- 332 A new transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma.
- 331 Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. **2022**, 2022, 1-27 0
- 330 Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. 0
- 329 Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. 0
- 328 Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. 1
- 327 Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. **2022**, 10, e004610 1
- 326 The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. **2022**, 23, 7839 0
- 325 Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral heterogeneity to immune escape.
- 324 Immunosenescence, inflammaging, and cancer immunotherapy efficacy. 1-12 1
- 323 Facts and hopes for immunotherapy in renal cell carcinoma. 2
- 322 Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. **2022**, 13, 1204 1
- 321 Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor. **2022**,
- 320 Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma. **2022**, 14, 859-869 1
- 319 Renal Tumors. **2023**, 285-308
- 318 Machine Learning for Computed Tomography Radiomics: Prediction of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma. Publish Ahead of Print,

- 317 The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. **2022**, 101819
- 316 Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation.
- 315 Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. 13, 0
- 314 Interferon- γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. 0
- 313 A rare case of a retrocrural lymph node metastasis from a chromophobe renal cell cancer (chRCC): complete thoracoscopic resection with a new multi-joint articulating surgical instrument.
- 312 A flexible approach for predictive biomarker discovery.
- 311 Neoadjuvant Immunotherapy in the Treatment of Renal Cell Carcinoma: A Case Series. **2022**,
- 310 Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL-2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
- 309 Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. **2022**, 13, 641-651
- 308 Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. **2022**, 13, 1211
- 307 Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. **2022**, 10, e004803 0
- 306 Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials. 2
- 305 C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. 1-8
- 304 Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. **2022**, 14, 3860
- 303 Recent Advances and Challenges in Cancer Immunotherapy. **2022**, 14, 3972 3
- 302 Aging-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity. 13,
- 301 SPP1 is expected to be a biomarker for predicting prognosis and immunotherapy efficacy in penile cancer patients.
- 300 Pre-treatment metastatic growth rate predicts clinical outcome of metastatic renal cell carcinoma treated with nivolumab.

- 299 Modeling Resistance to Immune Checkpoint Blockade. **2022**, 107-149
- 298 Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma. **2022**, 101, e29561
- 297 Exploratory treatment options fail in ccRCC.
- 296 Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience. 12, 1
- 295 Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. **2022**, 12, 1229
- 294 The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study.
- 293 IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. 12,
- 292 Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?. 1
- 291 Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12, 2
- 290 Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. **2022**,
- 289 Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. **2022**, 11, 2505 1
- 288 T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. **2022**, 23, 8590 0
- 287 The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. 13, 0
- 286 The epiphany derived from T-cell \uparrow inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. 13, 0
- 285 Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. **2022**, 10, e005147 0
- 284 A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. 13, 0
- 283 Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
- 282 Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma. **2022**, 2022, 1-16 0

281	Association between serum baseline C1q and IgG levels and the efficacy of combined immunotherapy in patients with esophageal squamous cell carcinoma: a retrospective study. 1-24	
280	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.	0
279	Computational design of PD-L1 small molecule inhibitors for cancer therapy.	2
278	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. 2022 , 114505	2
277	Nivolumab+Ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIg) treatment. 107815522211185	
276	Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. 12,	0
275	Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.	0
274	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. 2022 , 7, 100577	0
273	Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials. 2022 , 14, 175883592211261	0
272	Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. 2022 , 36, 039463202211255	0
271	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. 2022 , 14, 175883592211227	
270	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. 2022 , 14, 4192	0
269	The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.	0
268	Biomarkers in Urological Cancers. 2022 , 37-76	0
267	The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma. 13,	1
266	Relationships among microbiota, gastric cancer, and immunotherapy. 13,	0
265	Combating pancreatic cancer with ovarian cancer cells.	0
264	Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current clinical trials and future directions. 2022 , 1-10	0

263	Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. 2022 , 17, e0274451	0
262	A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs. 13,	0
261	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. 2022 , 11, 5611	1
260	Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. 2022 , 7,	2
259	ELEVATE Evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. 2022 , 22,	1
258	Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. 2022 , 11, 5171	0
257	Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. 13,	0
256	ACSL3 is a potential prognostic biomarker for immune infiltration in clear cell renal cell carcinoma. 9,	1
255	The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report. 2022 ,	0
254	Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. 1-11	2
253	Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-B ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. 2022 , 10, e005136	1
252	ImmunoPET Imaging with ⁸⁹ Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. OF1-OF10	1
251	The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. 2022 ,	0
250	METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. 10,	0
249	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. 13,	0
248	Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. 2022 , 2022,	0
247	Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. 2022 , 101, e30151	0
246	An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. 2022 , 11,	1

245	Targeting senescence as an anticancer therapy.	2
244	Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. 2022 , 101, e30333	0
243	Construction of an endoplasmic reticulum stress-related gene model for predicting prognosis and immune features in kidney renal clear cell carcinoma. 9,	1
242	The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. 2022 , 20,	0
241	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
240	Personalizing immunotherapy for renal cell carcinoma: how far have we come?. 1-5	1
239	Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. 2022 , 13,	1
238	Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. 12,	0
237	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. 12,	0
236	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.	0
235	Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma. 13,	0
234	DNA methylation-mediated low expression of ZNF582 promotes the proliferation, migration, and invasion of clear cell renal cell carcinoma.	0
233	First-in-human study of ONO -4578, an antagonist of prostaglandin E 2 receptor 4, alone and with nivolumab in solid tumors.	0
232	Associations between body composition features and clinical outcomes in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint blockade.	1
231	MTAP deficiency contributes to immune landscape remodeling and tumor evasion.	0
230	Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy. 1-12	0
229	Role of copper ionophore-induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis. 13,	0
228	Expression of Programmed Death-1 Ligand in Renal Cell Carcinoma and Its Relationship with Pathologic Findings and Disease-Free Survival. 2022 , 14,	0

- 227 Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. **2022**, 550, 215937 1
- 226 HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma. **2022**, 26, 101554 0
- 225 Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. **2022**, 1-33 0
- 224 Tratamiento del cáncer de riñón metastásico. **2022**, 54, 1-13 0
- 223 Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. **2022**, 0
- 222 Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. **2022**, 21, 135-141 0
- 221 Establishment and validation of a polygene prognostic model for clear cell renal cell carcinoma. 13, 0
- 220 A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas. 0
- 219 Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. **2022**, 30, 829-837 0
- 218 Immunoinfiltration-related gene SERPINE1 is a novel biomarker for diagnosis and prognosis of stomach adenocarcinoma discovered via high throughput transcriptome data mining combined with bioinformatics. 0
- 217 Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. **2022**, 14, 5078 1
- 216 Bifunctional anti-PD-L1/TGF- β II agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. **2022**, 20, 0
- 215 Precision Medicine in Oncology Drug Development. 1-15 0
- 214 Using machine learning and RNA to enhance the efficacy of anti-tumor immunotherapy. 0
- 213 Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment. 0
- 212 Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. **2022**, 1-9 0
- 211 PBRM1, SETD2 and BAP1 the trinity of 3p in clear cell renal cell carcinoma. 0
- 210 A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. **2022**, 0

209	Chromatin regulators-related lncRNA signature predicting the prognosis of kidney renal clear cell carcinoma and its relationship with immune microenvironment: A study based on bioinformatics and experimental validation. 13,	0
208	Phase I/ II study of multi-peptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.	0
207	Treatment of Refractory Metastatic Renal Cell Carcinoma. 2022 , 14, 5005	0
206	PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer. 2022 , 13,	0
205	Renal Cell Carcinoma. 1-10	0
204	Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Volume 14, 3071-3081	0
203	A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups. 2022 , 1877, 188825	0
202	Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomized, double-blind, multicentre phase III study (CONCEPT). 2022 ,	0
201	The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. 2022 , 11, 1521	0
200	FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. 2022 , 10, e005780	0
199	Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis. 2022 , 37, 100459	1
198	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. 2022 , 310, 121138	0
197	The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy. 2022 , 156, 113839	0
196	Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. 2022 , 35, 803-813	2
195	Impact of interaction networks of B cells with other cells on tumorigenesis, progression and response to immunotherapy of renal cell carcinoma: A review. 12,	0
194	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. 12,	0
193	The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. 2022 , 14, 5486	1
192	Engaging stemness improves cancer immunotherapy. 2022 , 216007	1

- 191 Consortium bibliometric analysis of hotspots and frontiers of immunotherapy in pancreatic cancer. ○
- 190 PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients. 11, 1281 ○
- 189 Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study. **2022**, 11, 3641 ○
- 188 Exploration of the role of Cuproptosis genes and their related long non-coding RNA in clear cell renal cell carcinoma: a comprehensive bioinformatics study. **2022**, 22, ○
- 187 Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead A Systematic Review. **2022**, 23, 14117 1
- 186 Contemporary Drug Therapy for Renal Cell Carcinoma Evidence Accumulation and Histological Implications in Treatment Strategy. **2022**, 10, 2840 ○
- 185 Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. ○
- 184 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13, ○
- 183 Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. **2022**, ○
- 182 Adjuvant therapy options in renal cell carcinoma Targeting the metastatic cascade. ○
- 181 French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. **2022**, 32, 1195-1274 ○
- 180 Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. **2022**, 8, 100202 ○
- 179 Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database. ○
- 178 Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma. **2023**, 225, 111457 ○
- 177 Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. **2023**, 181, 103881 ○
- 176 Current and Future Biomarkers in the Management of Renal Cell Carcinoma. **2023**, 50, 151-159 ○
- 175 Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. **2022**, 14, 175883592211340 1
- 174 The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. **2022**, ○

173	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. 2022 , 7, 131-149	1
172	The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis. 13,	1
171	Immune landscape and immunotherapy for penile cancer. 13,	0
170	How to Manage a Patient with Ocular Metastases?. 2022 , 10, 3044	0
169	Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. 12,	0
168	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.	0
167	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.	2
166	Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. 2022 , 12,	1
165	Development of therapeutic antibodies for the treatment of diseases. 2022 , 3,	1
164	Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. 1-8	0
163	EMILIN2 is associated with prognosis and immunotherapy in clear cell renal cell carcinoma. 13,	0
162	Current clinical perspective of urological oncology in the adolescent and young adult generation.	0
161	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022 , 22,	0
160	Current status and novel insights into the role of metastasectomy in the era of immunotherapy. 1-10	0
159	Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. 2022 , 40, 1583-1599.e10	1
158	Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. 2022 , 14, 6230	0
157	Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. 2022 , 15, 9082	0
156	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. 2022 , 108332	0

155	Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. 2022 , 22,	2
154	Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. 2022 , 14, 6167	4
153	Macrophage GSK3 β deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. 2022 , 10, e005655	0
152	Treatment of rheumatic adverse events of cancer immunotherapy. 2022 , 101805	2
151	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. 9,	0
150	Therapy-related myelodysplastic syndrome with monosomy 7 and metastatic renal cell carcinoma successfully treated with nivolumab: two birds with one stone.	0
149	Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis. 12,	0
148	The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. 2022 , 14, 6018	1
147	Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab.	0
146	Immune-based combination therapy for esophageal cancer. 13,	0
145	Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. 2022 , 22,	0
144	Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. 2022 , 14,	0
143	Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma. 2022 , 15,	0
142	T-cell repertoire diversity: friend or foe for protective antitumor response?. 2022 , 41,	0
141	Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. 2022 , 7, 100634	0
140	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. 2022 , 22,	0
139	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. 13,	0
138	Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC). 2022 , 10, 3244	0

- 137 ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. **2022**, 8, ○
- 136 Comprehensive analysis prediction prognosis and immune therapy value of angiogenesis-associated genes in kidney renal clear cell carcinoma. ○
- 135 CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. **2023**, 11, 165 1
- 134 Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. **2023**, 133, ○
- 133 Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. ○
- 132 Efficacy And Safety Of Nivolumab In Bone Metastases From Renal Cell Carcinoma: Results Of The Getug Afu 26 Nivoren Multicenter Phase Ii Study.. **2023**, ○
- 131 Prognostic role of the innate immune signature CD163 and Bat mβsignal calreticulin in clear cell renal cell carcinoma. ○
- 130 The Role of Immunotherapy in Renal Cell Carcinoma. **2023**, 1-31 ○
- 129 Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. **2023**, 73-84 ○
- 128 Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. **2023**, 15, 529 ○
- 127 A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs). 13, ○
- 126 Adjuvant Therapy in Renal Cell Carcinoma: Are we ready for prime time?. **2023**, 7, 1-11 ○
- 125 Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma. **2023**, 12, 349 ○
- 124 An Update on the Treatment of Papillary Renal Cell Carcinoma. **2023**, 15, 565 ○
- 123 The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. ○
- 122 Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. ○
- 121 Projecting overall survival in health-economic models: uncertainty and maturity of data. 1-12 ○
- 120 Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. **2023**, 248, 115064 ○

- 119 The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. **2022**, 101, e32393 ○
- 118 The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases. **2023**, 24, 297 ○
- 117 A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. ○
- 116 Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma. **2023**, 15, 266 1
- 115 Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. **2023**, 15, 216 ○
- 114 Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. **2022**, 14, 1419-1427 ○
- 113 Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states. ○
- 112 Development of a TGF- β -signaling-related genes signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma. 13, ○
- 111 Clear Cell Renal Cell Carcinoma: From Biology to Treatment. **2023**, 15, 665 2
- 110 Tumor immunology. **2023**, 245-452 ○
- 109 Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. **2023**, 11, e005924 ○
- 108 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 ○
- 107 Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. Volume 16, 49-64 ○
- 106 Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. ○
- 105 Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. **2023**, 13, ○
- 104 Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma. ○
- 103 The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis. **2023**, ○
- 102 Construction and verification of a novel prognostic risk model for kidney renal clear cell carcinoma based on immunity-related genes. 14, ○

- 101 Introduction on Cancer Immunotherapy. **2023**, 1-27 ○
- 100 A Case of Simultaneous Recurrence of Colorectal and Pancreatic Metastasis after Surgery for Renal Cell Carcinoma. **2023**, 56, 10-19 ○
- 99 Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. **2023**, 11, 304 ○
- 98 Immune-Related Adverse Events of the Gastrointestinal System. **2023**, 15, 691 ○
- 97 BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma. 13, ○
- 96 Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. **2023**, ○
- 95 Identification of a basement membrane-based risk scoring system for prognosis prediction and individualized therapy in clear cell renal cell carcinoma. 14, ○
- 94 Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm. **2023**, 34, 413-421 ○
- 93 Immunotherapy: Targeting Cancer Cells. **2023**, 179-217 ○
- 92 Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. **2023**, ○
- 91 Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. **2023**, 401, 796-798 ○
- 90 Exhausted intratumoral V α 19⁺ T cells in human kidney cancer retain effector function. **2023**, 24, 612-624 ○
- 89 Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer. **2023**, 15, 397-400 ○
- 88 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207 ○
- 87 Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC). **2023**, 3, 117-131 ○
- 86 Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. **2023**, 117, 109881 ○
- 85 Radiation Therapy in the Treatment of Localized and Advanced Renal Cancer. **2023**, 50, 325-334 ○
- 84 Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. **2023**, 183, 109618 ○

- 83 Metastasis in renal cell carcinoma: Biology and treatment. **2023**, 7, 100094 ○
- 82 Immune Checkpoint Inhibitors in Urological Cancers. **2023**, 1-25 ○
- 81 Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study. **2023**, 19, ○
- 80 Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNIP-RCC trial. ○
- 79 Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immuno-oncologic Predictive Factors. **2023**, 30, 203-210 ○
- 78 Cuproptosis related gene PDHB was identified as a biomarker and its up-regulation inhibited the invasion of renal clear cell carcinoma. ○
- 77 The role of immunotherapy in non-clear cell renal cell carcinoma. 13, ○
- 76 Expresión de PD-L1 en cáncer renal, características pronósticas y utilidad en la práctica clínica habitual. **2023**, ○
- 75 Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung Integrative analysis of immune infiltration and microenvironment characteristics in renal clear cell carcinoma induced by cell senescence. ○
- 74 ○
- 73 Nanomedicine for Combination Urologic Cancer Immunotherapy. **2023**, 15, 546 ○
- 72 Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. **2023**, 24, 3217 ○
- 71 Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. 14, ○
- 70 Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. 14, ○
- 69 Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?. **2023**, 15, 1048 ○
- 68 LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. **2023**, 19, 113-121 ○
- 67 Top 100 most-cited articles on renal cell carcinoma: A bibliometric analysis. **2023**, 102, e32926 ○
- 66 Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. **2023**, 23, ○

- 65 Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. ○
- 64 EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. **2023**, 10, ○
- 63 Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives. **2023**, 12, 1446 ○
- 62 Comprehensive Genomic Profiling ofNF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy. ○
- 61 Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma. **2023**, ○
- 60 Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality. 66-77 ○
- 59 Optimising Cancer Immunotherapy: Challenges and Opportunities. 26-43 ○
- 58 Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. ○
- 57 Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. **2023**, 24, 3994 ○
- 56 Licochalcone A Suppresses Renal Cancer Cell Proliferation and Metastasis by Engagement of Sp1-Mediated LC3 Expression. **2023**, 15, 684 ○
- 55 Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma. **2023**, 23, ○
- 54 The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. **2023**, 28, ○
- 53 The Changing Landscape of Immunotherapy for Advanced Renal Cancer. **2023**, 50, 335-349 ○
- 52 Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. **2023**, 4, 100947 ○
- 51 Association Between Survival and Metastatic Site in Mismatch RepairDeficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. **2023**, 6, e230400 ○
- 50 Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting. **2023**, 15, 1374 ○
- 49 Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. **2023**, 13, ○
- 48 Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. ○

- 47 Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy. 13, ○
- 46 Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. ○
- 45 Multimodal Treatments for Brain Metastases from Renal Cell Carcinoma: Results of a Multicentric Retrospective Study. **2023**, 15, 1393 ○
- 44 Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. ○
- 43 Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventive, retrospective-prospective cohort multicentre study. ○
- 42 Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. 14, ○
- 41 Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach. **2023**, 9, 236-248 ○
- 40 Ferredoxin 1, the key regulator of cuproptosis, was associated with prognosis and immune cell infiltration in clear cell renal cell carcinoma. **2023**, 2, ○
- 39 Kidney cancer treatment in the aging population. **2023**, 60, 20-24 ○
- 38 Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. **2023**, ○
- 37 Current Advances in Immune Checkpoint Therapy. ○
- 36 Molecular differences in renal cell carcinoma between males and females. ○
- 35 A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. **2023**, 24, 5332 ○
- 34 A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer. 13, ○
- 33 The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes. 14, ○
- 32 High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis. 14, ○
- 31 Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. **2023**, 13, 3702-3708 ○
- 30 An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines. **2023**, 24, 5648 ○

- 29 The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. 14, ○
- 28 HERVs and Cancer: A Comprehensive Review of the Relationship of Human Endogenous Retroviruses and Human Cancers. **2023**, 11, 936 ○
- 27 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 26 Treatment strategies for clear cell renal cell carcinoma: Past, present and future. 13, ○
- 25 Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?. ○
- 24 Editorial: Unravelling the sarcoma microenvironment: Impact of the genomic landscape on molecular signaling, immunosuppression, and treatment resistance. 13, ○
- 23 Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. 13, ○
- 22 Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. ○
- 21 Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy. 10, ○
- 20 Cancer Cell-Derived PDGFB Stimulates mTORC1 Activation in Renal Carcinoma. **2023**, 24, 6447 ○
- 19 New Progress of Immunotherapy in Gastric Cancer. **2023**, 13, 4904-4911 ○
- 18 Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. **2023**, 11, 1071 ○
- 17 AIM2 is a novel biomarker for predicting prognosis and immunotherapy response of clear cell renal cell carcinoma. ○
- 16 Trends in health care spending on kidney cancer in the United States, 1996-2016. ○
- 15 Newly developed 3D in vitro models to study tumor-immune interaction. **2023**, 42, ○
- 14 Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. ○
- 13 Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. **2023**, ○
- 12 Active recruitment of anti-PD-1 conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy. **2023**, 9, ○

- 11 Vascular mimicry induced by m6A mediated IGFL2-AS1/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. **2023**, 9, ○
- 10 Research Progress of Immunotherapy for Gastric Cancer. **2023**, 22, 153303382211505 ○
- 9 BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials. ○
- 8 Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer. ○
- 7 Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies; a rapidly evolving strategy. **2023**, 154473 ○
- 6 SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. **2023**, 24, 7505 ○
- 5 Association of human papillomavirus (HPV), p16, p53 and p63 expression with non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm construction for histopathological grading prediction. **2023**, 21, ○
- 4 Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. **2023**, 24, 7592 ○
- 3 Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study. **2023**, 15, 2394 ○
- 2 Nomograms for predicting overall survival and cancer-specific survival of patients with stage IV renal cell carcinoma: A SEER population-based study. **2023**, 2, e9130014 ○
- 1 Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors. 14, ○